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Abstract 
The effects of vinblastine (VLB) and its thirty-five known metabolites were investigated on nausea 
and alopecia associated receptors by means of molecular docking simulations. The in silico 
pharmacokinetics (PK) properties and binding affinities of VLB and its metabolites with the vinca 
site of tubulin were also elucidated in the present study.  
VLB and its metabolites have demonstrated binding affinities mainly for the muscarinic 
receptors M1, M4 and M5 that display significant roles in the onset of nausea during chemotherapy. 
The metabolites of VLB interact with the binding site of acetylcholine and share similar binding 
interactions with residues involved with the endogenous substrate. Furthermore, VLB metabolites 
have also shown binding affinities for alopecia associated receptors such as vitamin D (VDR), 
androgen, smoothened and MDM2, which can trigger the death of hair follicle following cancer 
treatment.  
The predicted PK properties of VLB and its metabolites have revealed that they are all 
substrates and inhibitors of CYP3A4 and P-glycoprotein, and inhibitors of CYP2D6. The majority 
of metabolites do not cross the blood-brain barrier, do not undergo glucuronidation and have no 
affinity for the human ether-à-go-go-related gene receptor. Finally, VLB metabolites docked into 
the vinca site of tubulin have revealed that metabolites 8, 10 and 11 have binding affinities for 
tubulin and interact with the same residues involved with VLB. Taking into account the PK 
properties, metabolite 10 (20-Hydroxy-VLB) has shown to be a potential active analog of VLB.  
This research project has aimed to a better understanding of the VLB-induced off-targets 
events such as nausea and alopecia, and how the VLB metabolites can trigger these ADRs. These 
findings suggest that knowing which and how the metabolites of VLB are involved with off-targets 
receptors of nausea and alopecia, as well as their PK properties and effects on tubulin target, ADRs 
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during chemotherapy could be eliminated or lessened. This is possible if modifications on the 
chemical structure of VLB and advances in drug discovery and medicinal chemistry fields are 
taken into consideration in future studies. It would enhance target specificity as it could decrease 
formation of many metabolites and hence minimize the number of off-target interactions. That 
could result in providing a less unpleasant treatment for cancer patients and a higher quality of life 
during chemotherapy.  
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CHAPTER 1 Introduction 
1.1 Cancer 
Cancer is a devastating disease that strikes millions of people with different age, sex and 
ethnicity. It occurs when healthy cells behave abnormally and start to proliferate out of 
control, thus spreading into surrounding tissues and causing tumors. According to the 
World Health Organization (WHO), 8.8 million people died from cancer in 2015 [1]. In 
Canada, cancer is the leading cause of deaths (30%) and estimated to affect half of 
Canadians in their lifetime [2, 3].  
Although sometimes considered fatal, 30%-50% of cancer types are preventable, 
and many are curable. The probability of developing cancer is dependent upon factors such 
as age, sex and daily life habits such as smoking, alcohol and obesity. As the population in 
Canada is aging, the incidence of cancer is likely to increase by 79% in the following years. 
The most common types of cancer in Canada are prostate and breast cancer thus annually 
affects around 100,000 males and women, respectively [2, 3].  
1.1.1 Treatment and Side Effects 
Chemotherapy is the most common type of treatment for cancer, especially if the disease 
has metastasized. It is chosen either as a single therapy or in combination with other types 
of cancer treatments such as surgery and radiation [4].  
Chemotherapy can be administered by different routes such as oral and intravenous 
(IV), which are the most used ones. Despite advances in its effectiveness, chemotherapy is 
well known to cause endless adverse drug reactions (ADRs) and thus decreases patient’s 
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quality of life and sometimes delays the treatment. The most common ADRs during 
chemotherapy are nausea, vomiting, diarrhea, fatigue, alopecia, neuropathy, anemia, 
anorexia and rash [5, 6]. Among those, nausea is undeniably the most prevalent and 
unpleasant ADR reported by patients during chemotherapy [6-9]. According to a study 
conducted by Kuchuk et al., 60 out of 100 patients have ranked nausea as the worst ADR 
during chemotherapy, thus even more unpleasant than fatigue, alopecia and motor 
neuropathy [9].  
1.2 Vinblastine 
Vinblastine (VLB) or vincaleukoblastine is an anticancer drug that was firstly isolated from 
the alkaloids of Madagascar periwinkle (Catharantus roseus) plant in 1960 in Canada [10]. 
(Figure 1.1) 
Along with other alkaloids derived from periwinkle plant such as vinorelbine, 
vindesine and vincristine, VLB is one of the major agents with antitumor properties used 
in chemotherapy [11]. These drugs act by inhibiting the polymerization of the microtubules 
(MTs) due to binding to the tubulin heterodimer, thus preventing the mitotic spindle, and 
the cell proliferation process. Usually administered in combined therapy, VLB is effective 
against a number of cancers such as renal cell carcinoma [12], Hodgkin’s lymphoma [13], 
small cell lung, breast and colon cancers [14].  
 Currently, the only route of administration of VLB is IV [15-19], by intermittent 
infusion over 1-15min [15, 20]. Interestingly, there have been studies showing the efficacy 
of VLB locally administered in patients with Kaposi’s sarcoma (KS), a very common 
associated disease with AIDS and diabetes that leads to unpleasant oral lesions. 
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Intralesional injections of VLB seems to ameliorate the symptoms in patients with KS [21, 
22]. However, it is strongly contraindicated by intrathecal route of administration due to 
its fatal risk. According to the Food & Drugs Administration (FDA), the pharmaceutical 
companies that manufacture VLB in the United States are Fresenius Kabi USA and  
West-Ward Pharms INT [23]. In Canada, VLB is commercialized by Pfizer and Sandoz 
pharmaceutical companies [17]. Further information is available through the most updated 
guide of drug information for health professionals and patients provided by BC Cancer 
Agency [15].  
1.2.1 Physicochemical Properties of Vinblastine 
VLB has a molecular weight (MW) of 812.99 g/mol and a chemical formula of 
C46H60N4O9, thus considered a large and complex structure. The catharantine portion (CT) 
of VLB (labelled C1ʹ-C26ʹ) has an unusual 9-membered ring named azacyclononane ring 
that contains a protonated and charged nitrogen atom at position 6ʹ, a hydroxyl and methyl 
group at C4ʹ, an ester group at C18ʹ and an indole ring. The vindoline portion (VD) of VLB 
(labelled N1-C30) is the major alkaloid from the periwinkle plant [24]. It also has an indole 
ring that contains an N-methyl at position 1 and a methoxy moiety at C16. It contains an 
ester and hydroxyl groups at C3, as well as an ester and ethyl groups at C4 and C5, 
respectively. According to the crystal structure of VLB, the molecule exists in dicationic 
form whereas the N6ʹ of catharantine portion and the N9 of vindoline portion are both 
protonated and positively charged [25].  (Figure 1.1) 
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Figure 1.1: Chemical structure of vinblastine. 
1.2.2 Vinblastine Target  
1.2.2.1 Microtubules 
The microtubules (MTs) are one of the main filaments of the cytoskeleton. They are 
responsible for a variety of intracellular mechanisms such as the transport of proteins, 
cellular signaling, maintenance of cell structure, segregation of chromosomes, protein 
trafficking and mitosis [26, 27]. The latter feature gained attention in the chemotherapeutic 
field as the MTs play a fundamental role in the mitotic spindle function during cell division, 
hence they could affect the cellular proliferation of cancer cells [28]. Therefore, the 
mechanism of action of drugs that target the MTs could inhibit the mitotic spindle, as well. 
The dynamics of the MTs are defined by the polymerization (assembly) and 
depolymerization (disassembly) states that in turn determine the cellular division [26].  
 Drugs that bind to the MTs are divided into two main classes of MT stabilizers and 
destabilizers agents. These drugs have different classifications and bind to different sites 
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in tubulin heterodimer. VLB is a microtubule-destabilizing agent whose binding site is 
located at the inter-dimer interfaces of α- and β-subunits of tubulin. Residues of helix H10 
of α-subunit of tubulin play a major role in the interactions with VLB and thus causes 
depolymerization of MTs [29].  (Figure 1.2) 
 
Figure 1.2:  Drugs that bind to the tubulin heterodimer. Subunits α- and β-tubulin are 
shown in blue and green, respectively. Drugs are shown in spheres within a circle. Helix 
H10 is shown in red. A) VLB (PDB entry 4EB6); B) Paclitaxel (PDB entry 1JFF), and C) 
Colchicine (PDB entry 4O2B).  
1.2.2.2 Vinblastine Binding Site  
The binding site of VLB is located in the inter-dimer interface of α- and β-subunits of 
tubulin, which is also known as the vinca site. In the β-tubulin subunit, the drug interacts 
with the carboxy-terminal of helix H6, loop T5 and helix H7. In the α-tubulin subunit, it 
binds to loop T7, helix H10 and strand S9 [27, 28]. Residues Phe351 and Val353 of  
α-tubulin and residues Lys176 (loop T5) and Tyr208 (helix H6) of β-tubulin make 
hydrogen bonds (H-bonds) with VLB [28]. Furthermore, residues Ala247, Leu248, 
Asn249, Pro325, Asn329, Lys352 of α-tubulin and residues Lys174 and Pro220 of β-
tubulin interact through hydrophobic interactions with VLB [28].  
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1.2.3 Absorption, Distribution, Metabolism, Excretion and Toxicity Properties of 
Vinblastine 
VLB is known to be highly distributed throughout the body. A study of combined therapy 
(Adriamycin, Bleomycin, Vinblastine and Dacarbazine) using VLB administered by IV 
injection in patients with Hodgkin’s lymphoma has shown that VLB reaches a maximum 
plasma concentration (Cmax) and maximum time (Tmax) of 7.95 μg/ml and 0.08 h, 
respectively [13]. This is due to the rapid plasma availability of VLB upon IV 
administration [13]. High Cmax and Tmax values lead VLB to have a very high area under 
the curve (AUC) as well as a long half-life (t1/2), thus increasing the renal elimination time 
from the body [13, 24]. Another contribution of slow excretion comes from the high 
percentage of drug bound to plasma proteins, to which VLB is 99% bound [15, 17]. Due 
to the high metabolism rate by the hepatobiliary system, the concentration of VLB is found 
50 to 100 times higher in the bile than in blood samples [30]. It seems that VLB does not 
undergo glucoronidation or sulfation during phase II drug metabolism [31]. Drug-drug 
interactions have been reported with epipodophyllotoxin, a class of anticancer drugs such 
as etoposide [31], CYP3A4 inhibitors and substrates, phenytoin and mitomycin [15].  
1.2.4 Vinblastine Adverse Drug Reactions 
It has been more than fifty years since VLB was approved, but the ADRs caused by the 
high drug toxicity remain poorly understood. The most common ADRs of VLB are nausea, 
vomiting, diarrhea, alopecia, myelosuppression and anemia [18, 24]. According to Lohr 
[32], Jordan et al. [33] and Shankar et al. [34], VLB has a minimal emetogenic risk of less 
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than 10%. On the other hand, the Clinical Guide to Antineoplastic Therapy [35], suggests 
that VLB is a moderate emetogenic agent as it occurs in 30%-60% of patients.  
1.3 Metabolites of Vinblastine 
Due to its molecular complexity, VLB is likely to form a variety of metabolites and hence 
lead to a variety of ADRs. However, the research for the identification of VLB metabolites 
and their elucidated chemical structures is still developing. The majority of the experiments 
regarding the identification of metabolites of VLB are performed in vivo, but lack the 
chemical elucidation of the possible compounds formed during the VLB metabolism.  
Three most recent studies have proposed a possible fragmentation of VLB. Twenty 
chemical structures were indicated as metabolites of VLB and elucidated in vitro through 
mass spectrophotometry technique [36-38]. (Figure 1.3) 
Moreover, an in vivo study of the metabolism of vinorelbine, an analog of VLB, 
has found possible metabolites for the anticancer drug [39]. The chemical structure of 
vinorelbine only differs from VLB in the catharantine portion which lacks the hydroxyl 
group observed in position C20ʹ of VLB. (Figure 1.1)  
de Grave et al. have identified ten products formed in vivo during the metabolism 
of vinorelbine [39]. Interestingly, a metabolite of vinorelbine which undergoes oxidation 
and cyclization in the vindoline unit was also previously elucidated by Elmarakby et al. as 
a possible metabolite of VLB [40], thus suggesting that vinorelbine and VLB may go 
through the same metabolic reactions. Moreover, de Grave et al. have considered two 
metabolic reactions for one metabolite of vinorelbine formed [39]. As the in vivo metabolic 
reactions of VLB have not been fully characterized yet, each metabolic reaction is 
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considered for one metabolite formed, thus totalizing fifteen metabolites of VLB formed 
in vivo. By saying that, there are thirty-five known metabolites of VLB identified up to 
date. (Figure 1.3) 
1.3.1 Vinblastine Metabolic Reactions  
VLB mainly undergoes hydroxylation, demethylation and hydrolysis reactions during its 
metabolism. The metabolites of VLB have their molecular mass varying from 353.44 g/mol 
to 828.99 g/mol, whereas only a minority of those have their MW increased due to aromatic 
hydroxylation [36-39]. The VD of VLB is more susceptible to metabolic reactions due to 
a high number of functional groups prone to metabolism. (Figure 1.3 and Table 1.1) 
1.4 Drug Administration, Distribution, Metabolism, Excretion and Toxicology 
1.4.1 Solubility, Log P, Log D and Human Jejunal Effective Permeability  
The predicted administration, distribution, metabolism, excretion and toxicology 
(ADMET) is based on different parameters related to the physicochemical properties of 
drugs. The measured solubility of drug-like compounds is obtained from three different 
fluid states: fasted state gastric fluid (FaSSGF), fasted state intestinal fluid (FaSSIF) and 
fed intestinal state fluid (FeSSIF). These fluids mimic the possible environments that a 
drug would encounter upon oral administration. According to Jantradid et al., a different 
pH, that corresponds to the in vivo characteristics, is calculated for each state fluid such as 
pH 1.6, 6.5 and 5.8 for FaSSGF, FaSSIF and FeSSIF, respectively [41]. 
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Figure 1.3: Metabolites of VLB. 
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Table 1.1: Metabolites of VLB, their metabolism reaction, location of reaction, and 
molecular weight. 
Metabolite Location Metabolic Reaction MW(g/mol) Ref. 
MTB1 C4 (VD) Ester hydrolysis 770.95 
[39] 
MTB2 C3 (VD) Deprotonation, oxidation, cyclisation 810.97 
MTB3 C6 (VD) Ollefin Hydroxylation 828.99 
MTB4 C7 (VD) Ollefin Hydroxylation 828.99 
MTB5 C16  (VD) O-demethylation 798.96 
MTB6 N1 (VD) N-demethylation 798.96 
MTB7 C12ʹ  (CT) Aromatic Hydroxylation 828.99 
MTB8 C13ʹ (CT) Aromatic Hydroxylation 828.99 
MTB9 C17 (VD) Hydroxylation 828.99 
MTB10 C20 (VD) Hydroxylation 828.99 
MTB11 N6ʹ (CT) N-oxidation 827.98 
MTB12 C16 (VD) O-demethylation 756.93 
MTB13 N1 (VD) N-demethylation 756.93 
MTB14 C16 (VD) O-demethylation 796.95 
MTB15 N1 (VD) N-demethylation 796.95 
MTB16 C3 (VD) Dehydration/(17)C-3-dehydration 794.98 
[36-
38] 
MTB17 C4ʹ (CT) Dehydration 794.98 
MTB18 C3 (VD) Hydrolysis of ester 752.94 
MTB19 C4 (VD) Hydrolysis of ester/ 752.94 
MTB20 C18ʹ (CT) Unknown  664.81 
MTB21 (VD) Retro Diels–Alder 651.86 
MTB22 C18ʹ (CT) Hydrolysis/Dehydration 354.44 
MTB23 C18ʹ (CT) Hydrolysis/Dehydration 353.44 
MTB24 C4ʹ (CT) Dehydration 734.92 
MTB25 C4ʹ (CT) Dehydration 734.92 
MTB26 C10 (VD) Unknown 526.6 
MTB27 C10 (VD) Unknown 524.67 
MTB28 (CT) Dehydration 664.81 
MTB29 (VD) Unknown 598.71 
MTB30 (VD) Oxidation 692.89 
MTB31 (VD) Unknown 544.70 
MTB32 (VD) Unknown 542.69 
MTB33 C4ʹ (CT) Dehydration 675.88 
MTB34 C18ʹ (CT) Hydrolysis of ester 484.65 
MTB35 C4ʹ (CT) Dehydration 466.64 
*CT: catharantine portion. VD: vindoline portion. 
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FaSSIF is correlated with the degree of drug hydrophobicity measured by log P, which is 
an octanol-water partition coefficient tool useful to measure the lipophilicity and 
hydrophilicity of a compound. If a compound has a high solubility rate in the intestines, it 
is likely to have a low log P, meaning that it is very hydrophilic. Very hydrophilic 
compounds are not able to successfully permeate the membranes as they lack a moderate 
hydrophilic/lipophilic balance, thus failing to be absorbed into the blood circulation and 
not achieving effectiveness. Therefore, drugs that have a low permeability across the 
intestinal membrane, known as the human jejunal effective permeability (Peff) are likely to 
be rapidly excreted from the body as they are not likely to cross the cell membrane and be 
absorbed by the body [42]. 
Log P is strongly related to many physicochemical properties that plays a role in 
the solubility, absorption, distribution, metabolism and clearance of drugs. The Rule of 
Five (RO5) proposed by Lipinski [43, 44], states that the log P should be less than 5 for a 
drug-likeness compound. Drugs with a low log P (<5) are considered hydrophilic 
compounds due to their polarity. They are also more prone to interact with plasmatic 
proteins and undergo to phase II metabolic conjugation reactions. On the other hand, 
structures with too many hydrophobic groups are expected to have a high log P (>5) [42, 
43]. The number of rotatable bonds (RB) and Log D value also play a role in the intestinal 
bioavailability for drug-like oral compounds [44]. A chemical drug with more than 10 RB 
and a log D higher than 0 and lower than 3 have low intestinal absorption [45]. 
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1.4.2 Volume of Distribution and Plasma Proteins 
The ratio of the amount of drug administered to the concentration that reaches to plasma 
or blood is defined as the volume of distribution (Vd). Thus, the Vd of a drug is useful to 
estimate the dose required to reach the plasma concentration determined for drug 
effectiveness. The prediction of the Vd is important as the dose required can vary depending 
on the height, weight and amount of fat tissue of each individual [46].  
Once the drugs reach the ideal plasma concentration in the blood system, they enter 
into the organs and tissues to encounter their respective target. However, if they have an 
affinity to bind to plasma proteins they remain in the blood circulation, and thus fail or take 
long to reach their target. Drugs that are more likely to bind to plasma proteins have polar 
functional groups in their structures and last a long time in the body due to their slow 
release time. The percentage of drug that is not bound to plasma protein is the free form of 
the drug which is able to reach its target [42]. 
1.4.3 P-glycoprotein and Human ether-à-go-go-related gene  
Among the most studied off-target receptors in drug discovery and in clinical research are 
permeability-glycoprotein (P-gp), human ether-à-go-go-related gene receptor (hERG) and 
cytochrome P450 complex [47]. P-gp belongs to the ABC transporters family as it is 
involved in drug cell efflux by using the energy produced by ATP hydrolysis [47]. P-gp is 
a transmembrane protein able to recognize a variety of xenobiotics due to its location at 
many different sites in the body such as the liver, intestine, brain and kidneys [48]. P-gp 
along with cytochrome P450 are the main enzymes that influence the pharmacotherapy 
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effectiveness as they are able to control cell efflux transporter and drug metabolism, 
respectively [49]. 
hERG is involved in the normal action potential of cardiac cells. The blockage of 
this receptor by xenobiotics is associated with many cardiovascular toxicities such as 
angina and ischemic events [50, 51].  
1.4.4 Cytochrome P450 Complex 
Cytochrome P450 complex is a superfamily of heme-containing enzymes that uses 
nicotinamide adenine dinucleotide phosphate (NADPH) as a co-factor to metabolize more 
than 90% of drugs. The main reactions that CYPs catalyze are hydroxylation, dealkylation, 
and heteroatom oxidation. From fifty-seven CYP isoforms, only nine are clinically relevant 
such as CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2E1, CYP2C9, CYP2C19, CYP2D6 
and CYP3A4. These metabolizing enzymes have more than 55% of sequence similarity 
and metabolize a great number of endogenous and exogenous compounds, either by 
oxidizing or reducing them [52].  
CYP3A4 is the main enzyme of CYP450 complex as it is responsible for the 
metabolism of 50% of drugs [47, 48, 53].  Usually, most of the drugs which are substrates 
and/or inhibitors of P-gp are also considered the same for CYP3A4 and vice-versa [54]. 
Essentially, drugs that are substrates of both P-gp and CYP3A4 are extremely important 
because these proteins are located in the hepatocytes and enterocytes, cells that are crucial 
for absorption and metabolism of drugs [55]. As part of phase I reactions, CYP450 
enzymatic complex is the main route by which drugs are metabolized. Compounds that 
undergo reactions with this complex aim to become more soluble for easier excretion from 
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the body. However, these enzymes can also trigger metabolic reactions that turn drugs and 
its metabolites into reactive compounds that can further bind to off-target sites [56]. 
1.4.4.1 CYP1A2, CYP2C8 and CYP2C9  
CYP1A2 have been described to facilitate the metabolism of certain class of medicines 
such as tricyclics antidepressants, antipsychotics, antihypertensive, and antiemetic drugs 
as ondansetron [57]. Ondansetron is a selective serotonin (5-HT3) receptor antagonist of 
nausea associated receptors and commonly used to treat nausea during chemotherapy. It is 
administered as a prophylactic treatment on the onset of symptoms [58, 59]. As a substrate 
of CYP1A2, ondansetron is also an inhibitor and substrate of CYP3A4 [60]. 
CYP2C8 is responsible for the metabolism of 35% of drugs due to its ability to 
accommodate large structures despite their hydrophobic character. The active site of this 
isoform is quite unique as it can, for instance, interact with anionic groups present in 
steroids and retinoid drugs [53].  
CYP2C9 is responsible for the metabolism of common and widely used class of 
drugs such as antidepressants and anti-inflammatories [57]. This isoenzyme is the most 
second abundant in the small intestine, only behind CYP3A4 [61].  
1.4.4.2 CYP2D6  
CYP2D6 accounts for less than 2% of the isoforms of CYP450 complex. However, it is 
known to metabolize more than 25% of the drugs. Its endogenous substrates are 
hydroxytryptamines and neurosteroids [62, 63] which are metabolized into serotonin, 
dopamine and testosterone [62]. Ligands having a lipophilic character contain a planar 
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hydrophobic component such as an aromatic ring. Drugs containing nitrogen atoms are 
likely to be protonated in the physiological pH and can also play a role in this enzyme [63]. 
It is noteworthy that this is a matter of chemical conformation and structure specificity 
within the active site of CYP2D6. Wang et al. have demonstrated that substrates of this 
enzyme are likely to have a nitrogen atom in 5-7 Å distant from the site of oxidation. 
Moreover, CYP2D6 triggers a variety of metabolic reactions such as demethylation, 
hydroxylation and oxidation [62]. The active site of CYP2D6 has an area of 540 Å2 and 
contains nearly 28 residues which are located around the heme group [64].  
1.4.4.3 CYP3A4  
The isoform CYP3A4 plays the greatest role in drug metabolism. It is found in the intestine 
and liver in high amounts, while its natural substrates include retinoic acids, steroids and 
bile acids [53]. CYP3A4 is considered the largest human enzyme of the CYP complex, 
formed by 502 residues (57.29 kDa). It has a reasonable variability among individuals due 
to differences in gender hormones, environment and genetic factors [65, 66].  
Because more than 60% of drugs are metabolized by CYP3A4, this enzyme is of 
extremely importance in drug-drug interactions caused by competition of CYP3A4. This 
can further account for a decrease of drug plasma concentration and poor treatment efficacy 
[65].  
CYP3A4 is located in the apex of enterocytes cells, a unique site that enhances the 
chances of this enzyme to meet xenobiotics that probably explains its main role in the 
metabolism first-pass effect [53]. The likelihood of binding of drugs is easily favored to 
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the CYP3A4 due to its active site being much larger than CYP2D6 (1385 Å2 vs. 540 Å2) 
[62, 66]. 
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1.5 Molecular Simulation 
1.5.1 Molecular Docking 
The pharmaceutical research field makes use of technologies based on structure-activity 
relationship (SAR) and structure-based drug design (SBDD) for the prediction of drug 
pharmacodynamics and pharmacokinetics (PK) properties, drug development and 
repositioning/repurposing, and protein-ligand molecular recognition [67]. Advances in 
protein purification, crystallography methods and nuclear magnetic resonance 
spectroscopy have vastly contributed to the medicinal chemistry research field due to the 
availability of knowledge of target protein structures and protein-ligand interactions [67, 
68]. In addition, developments within computational experiments as part of SBDD 
approaches have aided in the elucidation of the behavior of small molecules in the protein 
active site as well as protein-protein interactions in atomistic levels [67, 68]. One of the 
most useful and used applications in SBDD strategies is molecular docking techniques. 
Molecular docking is a key in silico tool that aims to predict the best conformation 
of the ligand into the binding pocket of a protein by calculating the binding energy of the 
ligand [67-69]. It requires two step process known as the conformational pose of the ligand 
in the protein binding site accessed by a sampling algorithm, and prediction of the binding 
affinity which is achieved by a scoring function [67, 68]. Thus, molecular docking 
experiments involve searching for the best conformation and scoring conformations based 
on their binding energy (i.e. a representation of affinity to the receptor). Koshland 
conceptualized the theory involving ligand-protein binding by suggesting that the 
interaction should be considered in flexible mode [70]. The “induced-fit” theory suggests 
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that as the ligand binds to the receptor, the protein active site changes its shape to fit the 
ligand [69, 70]. Thus, this theory defines that both receptor and ligand are flexible [68].  
Widely known software programs that adopt the flexible ligand docking include 
FlexX [69] and AutoDock [71]. Molecular docking programs are based on different 
sampling algorithms such as matching, genetic and incremental construction algorithms 
[67]. In addition, the best binding energy of the ligand predicted by molecular docking 
programs is calculated with different scoring functions such as knowledge-based, empirical 
and force-field-based [67, 68]. However, they all search for the best orientation pose and 
molecular interactions by considering all the inter-atomic forces between a ligand and its 
surrounding environment in the binding site. In particular, FlexX (used in this project), a 
commercial software package developed by BioSolveIT, is frequently utilized in the drug 
discovery field of small molecules and analysis of ligand-protein interactions. 
1.5.1.1 FlexX Algorithm and Scoring Function  
The search for the best conformation of a small molecule into the binding site of a protein 
depends on the torsional, translational and rotational degrees of freedom of the ligand as 
well as the interaction types and strength between a ligand and the binding site [67, 68]. 
Therefore, a great number of possible conformations can be adapted by either the 
ligand/protein or ligand-protein complex. Despite advances in the computer-aided drug 
discovery, it still takes a large amount of CPU time to generate all possible conformations. 
Thus the use of sampling algorithms is required to optimize this issue [68].  
FlexX uses an incremental construction algorithm that searches for the energetically 
favorable conformations of the ligand for their optimized binding to the protein target [69]. 
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Initially, it selects one of the fragments of the ligand by breaking the rotatable bonds and 
setting its moiety as a base-fragment in the binding site. Then it adds the remaining moieties 
of the ligand to the base-fragment [68, 69]. The order that the remaining fragments are 
added to the base-fragment depends on their favorable binding energies and orientation. 
For instance, those which are more prone to form H-bonds or salt bridges are added first. 
This is because these interactions are more geometrically and directionally stable [69]. The 
algorithm of FlexX constructs the ligand in an incremental fashion by finding the best 
binding mode of the ligand in the binding site of a protein and providing the total Gibbs 
energy of the ligand-protein complex.  
The foundation set for the best conformation of the ligand is based on the sum of 
all binding interactions between a ligand and the target receptor which mainly include 
hydrogen bonds (H-bond(s)) and hydrophobic interactions, electrostatic interactions, and 
van der Waals (vdW) forces [69, 72].  
Electrostatic interactions exist in both intramolecular and intermolecular forces. 
They comprise hydrogen bonds and ionic interactions, and follow Coulomb’s law, Vc. The 
sum of interactions among atoms i and j with two charges qi and qj and distance r is given 
below [73]: 
𝑉𝑐(𝑟𝑖𝑗) =
1
4𝜋𝜀0
𝑞𝑖𝑞𝑗
𝜀𝑟𝑟𝑖𝑗
              (𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏. 𝟏) 
Where ε0 is the electric constant or the vacuum permittivity that relates the units of 
electric charges to mechanical quantities; εr is the relative permittivity that is a decreased 
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factor relative to the vacuum due to the electric field between the charges, and π, which is 
the log (Px / PH) for a substituent X relative to a hydrogen substituent [73]. 
Van der Waals (vdW) force involves repulsive and attractive forces and is best 
known through the Lennard-Jones 12-6 function, VLJ. The intermolecular distance defined 
as rij, separates the interaction among atoms i and j, and thus vdW forces are calculated as 
given below [73]: 
𝑉𝐿𝐽(𝑟𝑖𝑗) = 4𝜀 [(
𝜎
𝑟𝑖𝑗
)
12
− (
𝜎
𝑟𝑖𝑗
)
6
]         (𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏. 𝟐) 
Where (𝑟𝑖𝑗)
12
 and (𝑟𝑖𝑗)
6
 are defined as the distance between atoms i and j, ε 
corresponds to the depth of the potential well, and σ is the finite distance at which the inter-
particle potential is zero [73].   
The output docking solutions for the ligands are ranked according to their total 
binding energy based on Böhm empirical scoring function [69, 72, 74, 75]. The Böhm 
scoring function, used in FlexX tool, estimates the free binding energy for the protein-
ligand complex, which is known as Gibbs energy (ΔGbinding) [72]. Thus, the best binding 
energy is the lowest binding energy (first rank) or the highest binding affinity. 
The approach used by Böhm which involves hydrogen bonding, ionic and 
hydrophobic interactions as well as the loss of internal degrees of freedom of the ligand as 
a result of binding is shown below: 
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∆𝐺𝑏𝑖𝑛𝑑𝑖𝑛𝑔 =  ∆𝐺0 +  ∆𝐺ℎ𝑏 ∑ 𝑓(∆𝑅, ∆𝛼)
ℎ−𝑏𝑜𝑛𝑑𝑠
 +  ∆𝐺𝑖𝑜𝑛𝑖𝑐 ∑ 𝑓(∆𝑅, ∆𝛼)
𝑖𝑜𝑛𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑠
+  ∆𝐺𝑙𝑖𝑝𝑜|𝐴𝑙𝑖𝑝𝑜| + ∆𝐺𝑟𝑜𝑡𝑁𝑅𝑂𝑇                      (𝑬𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝟏. 𝟑) 
Where ∆𝐺0 is the overall change in Gibbs rotational/translational degree of free 
energy; ∆𝐺ℎ𝑏 is the contribution of hydrogen bonds which is multiplied by a penalty 
function 𝑓(∆𝑅, ∆𝛼) derived from large geometric deviations such as distances and angles 
from an ideal hydrogen bond; the same is applied for ∆𝐺𝑖𝑜𝑛𝑖𝑐  function; hydrophobic 
interactions which are defined as ∆𝐺𝑙𝑖𝑝𝑜, are supposed to be proportional to the lipophilic 
contacts among ligand and protein, and is expressed by 𝐴𝑙𝑖𝑝𝑜. Finally, ∆𝐺𝑟𝑜𝑡𝑁𝑅𝑂𝑇 is the 
loss of Gibbs energy caused by the number of rotatable bonds of the ligand when it is bound 
to protein [72, 73]. 
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CHAPTER 2 Effects of Vinblastine and its Metabolites on Nausea 
Associated Receptors 
2.1 Introduction 
2.1.1 Chemotherapy-Induced Nausea and Vomiting  
Chemotherapy-induced nausea and vomiting (CINV) is the most common and unpleasant 
ADR during cancer treatment [1-4]. CINV is classified into three categories: i) acute onset, 
ii) delayed onset, and iii) anticipatory nausea and vomiting. This is, the onset of symptoms 
that can occur either in the first 24h, in the first five days or after a completed cycle of 
chemotherapy [1].  
The emetogenic profile of chemotherapeutic agents is defined as the relative 
percentage of the drug to induce emesis during chemotherapy. It is classified in four 
potential risks such as minimal (<10%), low (10-30%), moderate (30-90%) and high 
(>90%) [1, 5, 6]. CINV does not only impact the patient’s quality of life but can also lead 
to disease complications such as dehydration and malnutrition [1]. There are many 
prophylactic interventions to avoid or attenuate CINV with antiemetic drugs such as 
olanzapine, ondansetron or a combination of other nausea associated receptor antagonists 
[1, 7]. The American Society of Clinical Oncology provides the most updated guideline 
for antiemetics used in oncology [8]. However, CINV still remains an issue for the 
healthcare system and cancer patients.  
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2.1.2 Nausea Associated Receptors 
Nausea is stimulated by a variety of mechanisms in our body. For instance, the 
chemoreceptor trigger zone is located in the fourth ventricle and is a very vulnerable area 
found outside the blood brain barrier (BBB) [9]. This zone sends signals to the vomiting 
center when stimulated by xenobiotics such as the antineoplastic drugs, thus activates 
neurotransmitters such as dopamine and serotonin. The vestibular system responsible for 
the sense of balance and spatial orientation is mediated by the neurotransmitters 
acetylcholine (ACh) and histamine and it is also involved in nausea-induced symptoms. 
Other mechanisms such as the gastrointestinal (GI) tract and the cerebral cortex can also 
stimulate the vomiting center and cause emesis [9]. Flynn et al. have thoroughly 
investigated the main neurotransmitters involved in nausea and how this symptom is highly 
associated with anticancer drugs through the activation of nausea associated receptors [10].  
Dopamine, histamine, ACh and serotonin are the main neurotransmitters known to 
play important roles in emesis [10]. These molecules bind specifically to nausea associated 
receptors such as dopaminergic (D1, D2, D3, D4, D5), histaminic (H1, H2, H3, H4), 
muscarinic (M1, M2, M3, M4 and M5) and serotoninergic (5-HT1-5-HT7), respectively. They 
belong to the largest membrane bound family of proteins known as G-coupled protein 
receptors (GCPRs), which are responsible for a variety of mechanisms within the cell such 
as signaling, transport and response. Moreover, cannabinoid, corticosteroid, neurokinin-1, 
GABAminergic and opioids are also receptors included in nausea pathway, however, they 
are not discussed in this study [6, 9, 10].  
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2.1.2.1 Dopaminergic Receptors 
Dopaminergic receptors are classified into five different subtypes: D1, D2, D3, D4 and D5. 
These receptors share a high homology but distinct pharmacological features in between. 
For instance, D1R with D5R, as well as D2R with D3R and D4R share structure similarity, 
but they have different drug responses due to differences in their amino acid sequence. 
They are comprised of seven-transmembrane domains and their molecular mechanisms 
involve regulation of cAMP (cyclic adenosine monophosphate), which triggers a variety 
of biological signaling. Dopamine is the endogenous substrate of these receptors, known 
to play an important role in neurological dysfunctions such as Parkinson’s disease and 
schizophrenia. In particular, antagonists of dopaminergic receptors have been extensively 
studied for the treatment of nausea and psychological disorders [11]. These drugs act by 
inhibiting dopamine to bind to its receptor, thus prevent its activation. Osinski et al. have 
shown that D2R and D3R trigger emesis process in ferrets treated with specific receptor 
agonists [12].  
2.1.2.2 Histaminic Receptors 
A variety of mechanisms involved mainly in allergy and inflammation are unleashed 
through the activation of histaminic receptor subtypes H1, H2, H3 and H4 by its natural 
substrate, histamine. This endogenous compound also plays an important role in regulating 
the mucosa immunity, motility, neurotransmission and visceral nociception of the GI tract. 
The synthesis of the endogenous substrate occurs mainly in the mast cells, platelets and 
basophils cells via decarboxylation of histidine [13-15].  
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Sullivant et al. have shown that the presence of subtypes H1, H2, and H3 are more 
highly expressed throughout the GI tract of dogs with canine inflammatory bowel disease 
than the subtype H4 [15]. This is in agreement with previous research performed in humans 
that demonstrates similar distribution of histaminic receptors in the GI tract [16]. In 
particular, H1R is extensively distributed in the smooth muscle and gastric mucosa, and 
H3R is mainly found at the myenteric plexus, a major nerve supply also involved in motility 
[15, 16]. Therefore, the histaminic receptors, which are mainly involved in causing nausea 
are H1R and H3R. 
Among the antagonists of H1R, a class of drugs known as piperazines are often 
prescribed to control nausea symptoms in patients with cancer. A case report of 2008 in 
United Kingdom shows that cyclizine, a second generation of antagonists H1R, is effective 
in managing nausea induced by chemotherapy [17]. Studies of H1R antagonists have also 
demonstrated that this class of drugs are also effective in postoperative nausea and 
vomiting [18].  
2.1.2.3 Muscarinic Receptors 
The identified muscarinic receptors are divided into five subtypes: M1, M2, M3, M4 and 
M5, which all of them exhibit high sequence similarity with each other. Highly expressed 
in the parasympathetic system, these receptors regulate functions of the GI tract, endocrine 
and cardiac systems. The muscarinic receptors, also known as cholinergic receptors are 
expressed in the central nervous system. Thus, they are involved in memory, learning and 
cognitive functions, as well [19].  
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 The endogenous substrate responsible for the activation of muscarinic receptors, 
ACh, exerts physiological effects in hormonal and neuronal pathways. As ACh is found 
both in the vestibular and GI systems, antagonists of the natural ligand are useful drugs to 
treat nausea induced by different mechanisms. Anticholinergic agents such as scopolamine, 
a non-specific antagonist of muscarinic receptors, has been extensively studied for the 
relief of nausea caused by chemotherapy and/or postoperative situations [20]. More 
specifically, M1R and M5R antagonists have been reported as effective drug targets during 
nausea induced by cancer treatment [21, 22]. 
2.2 Material and Method 
2.2.1 Energy minimization 
A library consisting of the structures of VLB and its thirty-five known metabolites were 
built up using SYBYL®-X 2.1.1, a commercial molecular modelling and simulation 
package developed by Certera™. Metabolites were minimized step-wise using Pullman 
atomic charges and Tripos force field starting from 1.0 kJ/mol to 0.001 kJ/mol energy 
gradient each through 1000 iterations. In addition, the chemical structures of the natural 
substrates histamine, dopamine, and ACh were set to correct protonation states for 
molecular docking.  
2.2.2 Molecular Docking 
The natural endogenous substrates as well as the library of VLB and metabolites were 
docked into the binding pocket of each nausea associated receptors H1, H3, D2, M1, M4 and 
M5. These individual in silico experiments were carried out using FlexX program 
embedded in the LeadIT software package (version 2.1.8). Our laboratory has previously 
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performed studies with these nausea associated receptors. The homology modelling of the 
protein structures H3R, D2R, M1R, M4R and M5R used here have already been modelled 
and described elsewhere [10]. The crystalized structure of H1R was retrieved from the PDB 
entry 3RZE [14] where water molecules were removed, side chains and atom charges were 
calculated, and protonation states were adjusted for further energy minimization with 
AMBER7 FF99 force field. 
The binding pocket of H1R can accommodate two different charge states of the 
agonist histamine, dicationic with a protonated imidazole ring and monocationic with a 
neutral imidazole ring [23]. According to previous studies, all endogenous substrates of the 
nausea receptors have the amine group in the protonated state and are positively charged 
[23-26]. (Figure 2.1) 
 H1R: The binding pocket of H1R (PDB 3RZE), comprised of hydrophobic residues, 
is formed by three α-helices: α3 (residues 96-130), α5 (188-216) and α6 (408-441) [10, 
14]. The crystal structure used for H1R contains the antagonist doxepin that was used as a 
reference ligand for the docking experiments into H1R. A spherical region with a radius of 
20 Å surrounding doxepin was chosen as the target site for molecular docking of histamine, 
VLB and metabolites.  
H3R: The binding pocket of H3R (UniProtKB Q9Y5N1) is also formed by 
hydrophobic interactions that involves helices α3, α4 and α5 which respectively comprise 
residues 104-137, 141-178 and 196-225 [10, 13, 27]. A spherical region with a radius of 
20 Å around residue Asp114 located at α3 was selected as the target site for docking VLB, 
its metabolites and histamine into the binding site of homology model of H3R.  
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D2R: The binding pocket of D2R (UniProtKB P14416) is located between helices 
α3 (residues 104-137), α4 (151-171), α5 (187-220) and α6 (336-369), while residue 
Asp114 is involved in an H-bond with the endogenous substrate dopamine [10, 28-30]. 
Thus, a spherical region with a radius of 20 Å around Asp114 was defined as the target site 
for docking the library of metabolites, VLB and dopamine into D2R. 
M1R: The hydrophobic pocket located at helices α2, α6 and α7 are involved in the 
binding of ACh and antagonists into M1R (UniProtKB P11229), whereas α3, α4, α5, α6 
and α7 interact with the anticholinergic agents. To define the binding site of M1R, a 
spherical region with a radius of 20 Å around residue Asp105 was chosen as the target site 
for docking VLB, its metabolites and ACh. This residue is involved in the binding of 
agonists and antagonists of M1R through electrostatic interactions [10, 31, 32].  
M4R: For the binding pocket of M4R (UniProtKB P08173), a spherical region with 
a radius of 20 Å around residue Tyr113 was defined as the target site for docking VLB, its 
metabolites and ACh [32, 33].  
M5R: The binding site of M5R (UniProtKB P08912) is located between α2 
(residues 62-93), α3 (99-133), α4 (142-166), α5 (189-215), α6 (435-467) and α7 (472-495). 
A spherical region with a radius of 20 Å surrounding residue Asp109, which is involved in 
the agonist and antagonist interactions within M5R, was chosen as the target site for 
docking the natural substrate, VLB and its metabolites [10, 34].  
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Figure 2.1: Chemical structures of main neurotransmitters involved with the nausea 
associated receptors. 
 
2.2.3 In silico Prediction of Absorption, Distribution, Metabolism, Excretion and 
Toxicology Properties 
ADMET Predictor™ (version 7.2) [35] is a state-of-the-art software package developed by 
Simulation Plus, which predicts the Absorption, Distribution, Metabolism, Excretion and 
Toxicology (ADMET) properties of drugs or lead compounds with respect to their 
chemical structure. ADMET is used to calculate the pharmacokinetics and 
pharmacodynamics of molecular compounds by mimicking physiological conditions under 
pH 7.4. The parameters predicted by ADMET Predictor are based on pre-existing in vitro 
and in vivo data [35]. This software provides in silico data for over 140 PK parameters such 
as the gastric and intestinal solubility, log P, and the likelihood of drugs crossing the blood-
brain barrier (BBB). In addition, it calculates the affinity for a diverse number of 
proteins/enzymes or receptors involved in drug effectiveness and drug-drug interactions, 
such as P-glycoprotein, plasma proteins, human ether-à-go-go-related gene channel 
(hERG), as well as phase I and II metabolism. This is performed by assessing the likelihood 
of compounds binding to CYP450 enzymes and glucuronosyltransferases (UGT).  
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Our research group have recently investigated the ADMET properties of tamoxifen 
and its metabolites providing satisfactory results which are in agreement with previous in 
vivo and in vitro research [10]. In addition, other research such as El-Saadi et al. have 
demonstrated in-depth characterization of ADMET profile of promising analogs of 
fusarochromanone, a novel anticancer drug [36]. Through the use of ADMET Predictor, 
the authors have identified a few problematic areas that required further investigation for 
potential candidates for a drug-likeness compound, thus showing the software usefulness 
in predicting meaningful data prior to in vitro studies.  Therefore, due to its accuracy and 
satisfactory results, ADMET Predictor was chosen as an in silico modeling tool for 
prediction of the PK of VLB and its metabolites. 
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2.3 Results and Discussion 
VLB and its metabolites were docked into the nausea associated receptors D2, H1, H3, M1, 
M4 and M5 by means of molecular docking. The binding energy values and main binding 
interactions of VLB and its metabolites were compared to the known binding interactions 
of the endogenous substrates for each receptor, in order to evaluate their likelihood of 
inducing nausea during chemotherapy. 
2.3.1 Dopaminergic D2R 
Dopamine, VLB and its metabolites were docked into the binding site of D2R as described 
in the Materials and Method section of Chapter 2. (Table 2.1)  
2.3.1.1 Dopamine Binding to D2R 
The natural substrate of D2R, dopamine, interacts with residues Phe361 and Val115 
through hydrophobic contacts. Additionally, the hydroxyl groups of dopamine makes  
H-bonds with residue Ser193 (1.9 Å and 1.8 Å), and the amine group makes a H-bond and 
ionic interactions with residue Asp114 (1.8 Å). Dopamine has a binding energy of  
-12.89 kJ/mol for the binding site of D2R. (Figure 2.2B) 
2.3.1.2 Vinblastine Binding to D2R 
The binding energy of VLB for D2R is higher (-2.37 kJ/mol) than dopamine  
(-12.89 kJ/mol). VLB makes H-bonds with residues Glu181, Gln179, Glu95, and with the 
main chain of Leu94. Due to the binding affinity of VLB (-2.37 kJ/mol) for D2R and a lack 
of involvement with residues that bind to the natural substrate, it is suggested that the 
anticancer drug would not compete with dopamine for the binding site of D2R. (Figure 
2.2C) 
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Table 2.1: Binding energies of VLB, its metabolites and dopamine docked into D2R. The 
energy value of the metabolite with the lowest binding energy is shown in bold. 
D2R ΔGbinding (kJ/mol) 
Dopamine -12.89 
VLB -2.37 
MTB1 -5.54 
MTB2 -4.28 
MTB3 -10.17 
MTB4 -5.31 
MTB5 -9.61 
MTB6 -5.19 
MTB7 -1.61 
MTB8 -6.46 
MTB9 -0.89 
MTB10 -2.90 
MTB11 1.17 
MTB12 -8.02 
MTB13 -15.57 
MTB14 -9.65 
MTB15 -6.25 
MTB16 -5.29 
MTB17 -0.70 
MTB18 -17.51 
MTB19 -10.94 
MTB20 -0.78 
MTB21 -10.90 
MTB22 -17.07 
MTB23 -15.40 
MTB24 -13.26 
MTB25 -9.34 
MTB26 -14.12 
MTB27 -10.05 
MTB28 -3.07 
MTB29 -13.11 
MTB30 -14.17 
MTB31 -9.68 
MTB32 -6.03 
MTB33 -7.94 
MTB34 -17.58 
MTB35 -12.45 
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2.3.1.3 Metabolites Binding to D2R 
The majority of metabolites of VLB would not play a role in the binding site of D2R due 
to their binding energies. However, metabolite 34 interacts stronger than the dopamine for 
D2R, with a binding energy of -17.58 kJ/mol compared to -12.89 kJ/mol, respectively. The 
protonated nitrogen atom from the azacyclononane ring as well as the hydroxyl group 
establish H-bonds with the binding site of D2R through residues Glu95 and Leu94. 
Metabolite 34 makes hydrophobic interactions with residues Asn367, Ile183, Phe110 and 
Tyr379. Therefore, it is suggested that metabolite 34 competes with dopamine for the 
binding site of D2R due to its binding energy (-17.58 kJ/mol). (Table 2.1 and Figure 2.2D) 
 
Figure 2.2: A) Pose view of dopamine docked into D2R. B) Binding interactions of 
dopamine; C) VLB, and D) Metabolite 34. Hydrogen bonds are shown in dashed lines. 
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2.3.2 Histaminic H1R 
VLB, its metabolites and histamine were docked into the binding pocket of H1R as 
described in the Materials and Method section of Chapter 2. The docking results of 
histamine, VLB and its metabolites into the binding site of H1 receptor demonstrates that 
only three metabolites (metabolites 22, 23 and 35) have a strong binding energy for the 
binding pocket of the natural substrate, whereas metabolite 22 has the lowest binding 
energy of -18.10 kJ/mol. (Table 2.2) 
2.3.2.1 Histamine Binding to H1R 
The imizadole ring of histamine makes H-bonds with residues Asp178 (2.2 Å) and the 
protonated amine makes ionic interactions and H-bonds with Asp107 (1.9 Å and 2.3 Å) 
within the binding site of H1R. Moreover, histamine also interacts with residues Ile454 and 
Tyr431 through hydrophobic contacts with a binding energy of -14.40 kJ/mol for H1R. 
(Table 2.2 and Figure 2.3B) 
2.3.2.2 Vinblastine Binding to H1R  
The binding energy of VLB in the binding pocket of H1R is -0.17 kJ/mol. VLB makes  
H-bonds with residues Arg175, Arg97 and Trp93, whereas both methyl groups of esters 
and the hydroxyl group are involved in these interactions. Although VLB is able to interact 
with H1R, it would not play a role in this receptor. This is because VLB does not interact 
with the same residues involved in the binding of the natural substrate and has a binding 
energy of only -0.17 kJ/mol for H1R. (Figure 2.3C) 
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Table 2.2: Binding energies of VLB, its metabolites and histamine docked into H1R. The 
energy value for the metabolite with the lowest binding energy is shown in bold. 
H1R ΔGbinding (kJ/mol) 
Histamine -14.40 
VLB -0.17 
MTB1 0.82 
MTB2 13.98 
MTB3 0.37 
MTB4 -0.08 
MTB5 -2.15 
MTB6 2.83 
MTB7 4.25 
MTB8 -2.65 
MTB9 4.19 
MTB10 0.32 
MTB11 -0.96 
MTB12 0.82 
MTB13 -7.90 
MTB14 -3.42 
MTB15 5.24 
MTB16 0.92 
MTB17 -2.71 
MTB18 -12.23 
MTB19 -7.05 
MTB20 -6.83 
MTB21 -8.84 
MTB22 -18.10 
MTB23 -15.13 
MTB24 -7.64 
MTB25 -7.62 
MTB26 -6.99 
MTB27 -8.29 
MTB28 -0.20 
MTB29 -12.00 
MTB30 -8.10 
MTB31 -9.49 
MTB32 -7.53 
MTB33 -7.11 
MTB34 -13.35 
MTB35 -15.30 
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2.3.2.3 Metabolites Binding to H1R  
The metabolites of VLB that are more likely to display a significant role in the functionality 
of H1R are metabolite 22, metabolite 23 and metabolite 35 due to their binding energies. 
(Table 2.2) 
Metabolite 22 has a binding energy of -18.10 kJ/mol when docked into H1R. It 
interacts with residues from helices α5 and α6 of H1R such as Asp183. Hydrogen bonds 
are observed with residues Asp183 (2.0 Å and 1.9 Å) and Arg175 (1.7 Å), and hydrophobic 
interactions with residues Phe184, Tyr185 and Arg97. Therefore, metabolite 22 competes 
with histamine for its binding site due to its binding energy for H1R (-18.10 kJ/mol). Thus, 
it is suggested that metabolite 22 may account for nausea during chemotherapy with VLB 
through interaction with H1R. (Figure 2.3D) 
 
Figure 2.3: A) Pose view of histamine docked into H1R. Binding interactions of B) 
Histamine; C) VLB; and D) Metabolite 22. Hydrogen bonds are shown in dashed lines. 
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2.3.3 Histaminic H3R 
Histamine, VLB and its metabolites were docked into the binding pocket of H3R as 
described in the Materials and Method section of Chapter 2. (Table 2.3) 
2.3.3.1 Histamine Binding to H3R 
Histamine has a binding energy calculated of -13.42 kJ/mol when docked into H3R. The 
imidazole ring makes an H-bond with residue Asp114 (2.1Å), the charged amine makes 
H-bonds with residues Ser121 and Asp80 (2.1 Å and 1.8 Å, respectively). Moreover, 
hydrophobic interactions are seen among the aliphatic chain of histamine and residue 
Trp371. (Table 2.3 and Figure 2.4B) 
2.3.3.2 Vinblastine Binding to H3R  
In the binding site of H3R, VLB has a binding energy of -13.78 kJ/mol, whereas the 
azacyclononane ring makes an H-bond with the main chain of residue Cys188 (1.8 Å). 
Residues Tyr194, Phe193, Tyr115, Arg381 and Tyr94 also participate in interactions with 
VLB within the binding site of H3R. VLB and histamine have very close binding energies 
(-13.78 kJ/mol vs. -13.42 kJ/mol). Although they do not interact with the same residues, it 
is possible that VLB competes with histamine for the binding site of H3R. (Table 2.3 and 
Figure 2.4C) 
2.3.3.3 Metabolites Binding to H3R  
All of the metabolites of VLB have some degree of binding affinity for H1R. Metabolite 
18 has the lowest binding energy among the metabolites of VLB (-19.67 kJ/mol vs. to  
-13.42 kJ/mol) docked into H3R. Similar to VLB, metabolite 18 is located at the entrance 
of the binding pocket. (Table 2.3 and Figure 2.4A) 
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Table 2.3: Binding energies of VLB, its metabolites and histamine docked into H3R. The 
energy value for the metabolite with the lowest binding energy is shown in bold. 
H3R ΔGbinding (kJ/mol) 
Histamine -13.42 
VLB -13.78 
MTB1 -12.97 
MTB2 -11.07 
MTB3 -11.97 
MTB4 -12.30 
MTB5 -15.95 
MTB6 -13.42 
MTB7 -12.23 
MTB8 -11.11 
MTB9 -6.71 
MTB10 -9.35 
MTB11 -8.36 
MTB12 -16.19 
MTB13 -13.77 
MTB14 -12.36 
MTB15 -15.00 
MTB16 -15.40 
MTB17 -11.77 
MTB18 -19.67 
MTB19 -16.74 
MTB20 -9.70 
MTB21 -16.81 
MTB22 -18.49 
MTB23 -13.44 
MTB24 -15.29 
MTB25 -13.94 
MTB26 -12.42 
MTB27 -17.74 
MTB28 -11.97 
MTB29 -17.39 
MTB30 -19.55 
MTB31 -14.86 
MTB32 -13.63 
MTB33 -13.62 
MTB34 -17.96 
MTB35 -17.46 
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Metabolite 18 makes H-bonds with residues Tyr115, Cys188 and Arg381, whereas residue 
Tyr115 binds to the carbonyl group of ester, and the main chain of Cys188 interacts with 
the hydroxyl group of the vindoline unit. In addition, residues Tyr94 and Tyr194 interact 
through hydrophobic contacts with metabolite 18. Therefore, due to the binding energy of 
metabolite 18 (-19.67 kJ/mol), this metabolite competes with histamine for the binding 
pocket of H3R. However, it mainly interacts with the residues in proximity of those 
interacting with histamine, similar to VLB. (Figure 2.4D) 
 
Figure 2.4: A) Pose view of histamine docked into H3R. B) Binding interactions of 
histamine; C) VLB; and D) Metabolite 18. Hydrogen bonds are shown in dashed lines. 
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2.3.4 Muscarinic M1R 
VLB, its metabolites and acetylcholine were docked into the binding pocket of M1R as 
described in the Materials and Method section of Chapter 2. (Table 2.4) 
2.3.4.1 Acetylcholine Binding to M1R 
Acetylcholine (ACh) has a binding energy of -4.79 kJ/mol in the binding site of M1R, 
whereas it makes H-bonds with residues Tyr404 and Tyr106, within a distance of 2.2 Å 
and 2.4 Å, respectively. Hydrophobic interactions are seen among the N-trimethyl group 
of ACh and residues Asp105 and Tyr381. (Figure 2.5B) 
2.3.4.2 Vinblastine Binding to M1R  
VLB has a lower binding affinity than ACh for M1R (binding energies of -3.77 kJ/mol vs.  
-4.79 kJ/mol, respectively). H-bonds are seen with residues Leu183 and Ser388 with the 
catharantine portion of VLB. Moreover, residue Gln177 interacts with the ester group at 
C4 of vindoline portion, and residues Trp400, Tyr404 and Tyr179 make hydrophobic 
interactions with VLB. VLB interacts hydrophobically with residue Tyr404 which is also 
involved in the binding of ACh, thus it may contribute to nausea during chemotherapy. 
(Figure 2.5C) 
2.3.4.3 Metabolites Binding to M1R  
The metabolites of VLB that would play major role in the activation of M1R are metabolites 
22 and 23 due to their binding energies for the binding site of M1R (-18.10 kJ/mol and  
-16.86 kJ/mol, respectively) and similar interaction profiles as of ACh. 
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Table 2.4: Binding energies of VLB, its metabolites and acetylcholine docked into M1R. 
The energy value for the metabolite with the lowest binding energy is shown in bold. 
M1R ΔGbinding (kJ/mol) 
Acetylcholine -4.79 
VLB -3.77 
MTB1 -6.65 
MTB2 -4.19 
MTB3 -2.70 
MTB4 -4.61 
MTB5 -3.58 
MTB6 -6.43 
MTB7 -2.48 
MTB8 -1.89 
MTB9 -3.44 
MTB10 -6.24 
MTB11 -4.78 
MTB12 -6.30 
MTB13 -8.47 
MTB14 -12.17 
MTB15 -8.07 
MTB16 -7.17 
MTB17 -1.73 
MTB18 -17.01 
MTB19 -14.27 
MTB20 -5.33 
MTB21 -13.52 
MTB22 -18.24 
MTB23 -16.86 
MTB24 -15.14 
MTB25 -14.63 
MTB26 -13.84 
MTB27 -15.51 
MTB28 -4.72 
MTB29 -16.00 
MTB30 -17.73 
MTB31 -13.47 
MTB32 -11.67 
MTB33 -13.62 
MTB34 -17.90 
MTB35 -14.96 
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Metabolite 22 has the lowest binding energy among the metabolites of VLB docked into 
M1R, calculated as -18.24 kJ/mol. The binding energy of metabolite 22 is more than three 
times stronger than the binding energy of ACh (-4.79 kJ/mol). (Table 2.4) 
Metabolite 22 makes a H-bond with residue Asn382 within a distance of 1.6 Å and 
interacts hydrophobically with residues Ala193, Tyr381, Tyr106 and Phe197. Metabolite 
22 shares common residues (Tyr106 and Tyr381) with ACh within the binding pocket of 
M1R. Thus, it is suggested that metabolite 22 may induce nausea during chemotherapy with 
VLB due to its binding energy (-18.24 kJ/mol) for M1R and similar interaction profile as 
of ACh (Tyr106 and Tyr381). (Figure 2.5D and Figure 1.3-M22) 
 
Figure 2.5: A) Pose view of acetylcholine docked into M1R. Binding interactions of B) 
ACh; C) VLB, and D) Metabolite 22. Hydrogen bonds are shown in dashed lines. 
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Residues Tyr106 and Tyr404 which are involved in the binding of ACh into the binding 
site of M1R, also interact with metabolite 23. A H-bond is observed among residue Tyr106 
and the ester group of metabolite 23, within a distance of 1.7 Å. This interaction is 0.7 Å 
shorter than the binding of ACh with residue Tyr106 (2.4 Å). Moreover, residue Tyr404 
interacts with the protonated nitrogen of indole ring at a distance of 1.6 Å, 0.6 Å shorter 
than ACh and Tyr404 (2.2 Å). Besides stronger H-bonds with residues Tyr106 and Tyr404 
(1.7 Å and 1.6 Å) with M1R than the natural substrate (2.4 Å and 2.2 Å), metabolite 23 also 
makes H-bonds with the main chains of residues Leu183 and Ile180. Therefore, due to 
binding energy of metabolite 23 as well as similar interaction profile as of ACh, it is 
suggested that this metabolite may contribute to nausea during chemotherapy with VLB 
through activation of M1R. (Figure 2.6 and Figure 1.3-M23) 
 
Figure 2.6: Binding interactions of metabolite 23 (yellow) docked into the binding site of 
M1R and similar interaction profile as of ACh (white). Hydrogen bonds are shown in 
dashed lines.   
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The remaining metabolites of VLB also bind to the binding site of M1R, however, they do 
not show the same interaction profile as of ACh, which suggests that those metabolites are 
less likely to activate the receptor during nausea. Nevertheless, metabolites 22 and 23 have 
significant binding affinities for M1R, and share similar binding interactions as of ACh 
(Tyr106, Tyr404 and Tyr381), hence could induce for nausea during treatment with VLB. 
 
2.3.5 Muscarinic M4R 
VLB, its metabolites as well as ACh were docked into the binding site of M4R as described 
in the Materials and Method section of Chapter 2. (Table 2.5) 
2.3.5.1 Acetylcholine binding to M4R 
ACh interacts with residues Tyr439, Tyr113 and Asp112 in the binding site of M4R through 
hydrophobic contacts and H-bonds. The carbonyl of ester group of ACh makes an H-bond 
with Tyr439 (3.0 Å) and Tyr113 (2.2 Å), and contributes to a binding energy of  
-7.65 kJ/mol for ACh docked into M4R. (Figure 2.7A and 2.7B)  
2.3.5.2 Vinblastine Binding to M4R  
VLB has a binding energy of -3.90 kJ/mol docked into M4R and interacts with residue 
Tyr92 through an H-bond. In addition, residues Ile93 and Gln184 make hydrophobic 
interactions with VLB. However, due to its binding energy of -3.77 kJ/mol vs. -7.65 kJ/mol 
for ACh, as well as having similar binding profile to ACh, VLB would not play a role in 
the binding site of M4R. (Figure 2.7C) 
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Table 2.5: Binding energies of VLB, its metabolites and acetylcholine docked into M4R. 
The energy value for the metabolite with the lowest binding energy is shown in bold. 
M4R ΔGbinding (kJ/mol) 
Acetylcholine -7.65 
VLB -3.90 
MTB1 -9.98 
MTB2 -15.14 
MTB3 -6.71 
MTB4 -4.09 
MTB5 -9.15 
MTB6 -4.16 
MTB7 -3.85 
MTB8 -4.02 
MTB9 -5.58 
MTB10 -10.16 
MTB11 -6.82 
MTB12 -10.28 
MTB13 -20.65 
MTB14 -17.36 
MTB15 -14.52 
MTB16 -10.18 
MTB17 -6.14 
MTB18 -17.19 
MTB19 -18.63 
MTB20 -10.87 
MTB21 -10.87 
MTB22 -16.71 
MTB23 -16.63 
MTB24 -14.88 
MTB25 -15.48 
MTB26 -12.38 
MTB27 -18.40 
MTB28 -6.79 
MTB29 -17.66 
MTB30 -14.96 
MTB31 -11.31 
MTB32 -14.72 
MTB33 -12.53 
MTB34 -17.09 
MTB35 -13.74 
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2.3.5.3 Metabolites Binding M4R  
Some metabolites of VLB have significant binding affinities for M4R. For instance, 
metabolite 13 has the strongest binding affinity among the metabolites, according to its 
binding energy of -20.65 kJ/mol when docked into the binding site of M4R. The binding 
energy calculated is more than twice that of ACh (-7.65 kJ/mol). Metabolite 13 makes  
H-bonds with residues Ile187, Gln427 and Asn423. In addition, residue Tyr439, which is 
also involved in the binding of ACh, makes hydrophobic interactions with the ethyl group 
of metabolite 13. Moreover, residues Phe186, Leu190 and Cys185 also interact 
hydrophobically with metabolite 13. Therefore, metabolite 13 could potentially contribute 
to nausea during chemotherapy with VLB due to its binding affinity for M4R (-20.65 
kJ/mol). (Figure 2.7D) 
 
Figure 2.7: A) Pose view of ACh docked into M4R. Binding interactions of B) ACh; C) 
VLB, and D) Metabolite 13. Hydrogen bonds are shown in dashed lines.  
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Many of VLB metabolites have better binding energies for M4R than ACh, however their 
interaction profile are different from ACh, which could result in different induced effect 
during the signaling process. The metabolites that have binding affinities for M4R and 
display similar interaction profiles to that of ACh are metabolite 19, metabolite 18, 
metabolite 34, metabolite 22, metabolite 23 and metabolite 10. Thus, it is suggested that 
these metabolites could trigger the onset of nausea during chemotherapy with VLB. 
Metabolite 19 has binding energy of -18.63 kJ/mol docked into M4R. Its affinity is 
mainly due to hydrophobic interactions and a H-bond with residue Tyr439 which is also 
involved in the binding of ACh. Residue Tyr439 interacts with metabolite 19 within a 
distance of 2.2 Å, 0.8 Å shorter than ACh (3.0 Å). Hydrophobic contacts are seen with 
Trp435 and Cys185. Therefore, metabolite 19 contributes to nausea during chemotherapy 
with VLB due to its binding affinity for M4R (-18.63 kJ/mol) and a similar interaction 
profile. (Figure 2.8A) 
Metabolite 18 also binds to residue Tyr113 within a distance of 2.1 Å, which is  
0.1 Å shorter than of that by ACh (2.2 Å). In addition, it makes H-bonds with residues 
Asn423 and Ile187, and contributes to a binding energy of -17.19 kJ/mol and its likelihood 
of activating M4R during treatment with VLB. (Figure 2.8B) 
Metabolite 34 has a binding energy of -17.10 kJ/mol when docked into the binding 
site of M4R. It also makes a H-bond with residue Tyr439 within a distance of  
2.2 Å, which is 0.8 Å shorter than the natural substrate (3.0 Å). In addition, it interacts with 
Asp432 and Trp435, suggesting that metabolite 34 may trigger nausea symptoms during 
chemotherapy with VLB. (Figure 2.8C) 
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Metabolite 22 has a calculated binding affinity of -16.71 kJ/mol for M4R. It makes 
hydrophobic interactions with residues Tyr113 and Tyr439, which are involved with the 
binding of ACh. This interaction is different than between Tyr113 and ACh. However, 
metabolite 22 has additional interactions with the binding pocket of M4R, as it interacts 
with residues Asn417, Trp413 and Ser116, which in turn contribute to its binding energy. 
Metabolite 22 competes with ACh for binding to M4R and potentially activates the receptor 
during nausea. (Figure 2.8D) 
Metabolite 23 has a binding energy of -16.63 kJ/mol, more than double the binding 
energy of ACh (-7.65 kJ/mol) for M4R. Residues Tyr113 and Tyr439 which are involved 
in the binding of ACh, interact with the ester group and the protonated nitrogen of the 
indole ring of metabolite 23, respectively. Although the distance between residue Tyr113 
and metabolite 23 (2.7 Å) is 0.5 Å longer than that of ACh (2.2 Å), this metabolite is 1.4 
Å closer than ACh in the binding of residue Tyr439 (1.6 Å vs. 3.0 Å). Because metabolite 
23 interacts with the same residues as ACh in M4R, it is suggested that this metabolite may 
induce nausea during chemotherapy with VLB. (Figure 2.8E) 
Metabolite 10 (20-hydroxy-VLB) has a binding energy of -10.16 kJ/mol and also 
interacts with residues Tyr439 and Tyr113. The protonated nitrogen of azacyclononane 
ring makes one H-bond with Tyr439 within a distance of 1.8 Å. This interaction is 1.2 Å 
shorter than of that with the natural substrate (3.0 Å). Tyr113 makes hydrophobic contacts 
with metabolite 10 instead of an H-bond seen with ACh. Hydrophobic interactions are seen 
with Trp435, Gln427 and Phe186. Therefore, due to the binding affinity of metabolite 10 
for M4R and similar involving residues (Tyr113 and Tyr439) in the binding of the natural 
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substrate, this metabolite may activate nausea symptoms during treatment with VLB. 
(Figure 2.8F) 
 
Figure 2.8: Binding interactions of A) Metabolite 19; B) Metabolite 18; C) Metabolite 34; 
D) Metabolite 22; E) Metabolite 23, and F) Metabolite 10 docked into M4R. Hydrogen 
bonds are shown in dashed lines. 
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2.3.6 Muscarinic M5R 
ACh, VLB and its metabolites were docked into the binding site of M5R as described in 
the Materials and Method section of Chapter 2. (Table 2.6) 
2.3.6.1 Acetylcholine Binding to M5R 
The binding energy calculated for ACh docked into M5R is -4.51 kJ/mol. ACh binds to 
residues Tyr480, Tyr110 and Tyr457. The carbonyl group of ACh makes H-bonds with 
residues Tyr480 and Tyr110 within a distance of 2.6 Å and 2.2 Å, respectively. 
Hydrophobic interactions are seen with residues aforementioned as well as with Tyr457 
and Asp109. (Figure 2.9B) 
2.3.6.2 Vinblastine Binding to M5R 
VLB has a binding energy of -9.28 kJ/mol for M5R, approximately ~4 kJ/mol lower than 
that of ACh (-4.51 kJ/mol). VLB makes H-bonds with residues Asp468 and Gln183. The 
hydroxyl group and the protonated nitrogen both make H-bonds with Asp468, within a 
distance of 1.6 Å and 1.9 Å, respectively. The charged nitrogen atom in the azacyclononane 
ring of VLB also makes an ionic interaction with Asp468. In addition, Gln183 interacts 
with the carbonyl ester group (2.2 Å). Hydrophobic interactions among the aforementioned 
residues (Asp468 and Gln183) as well as with Trp476 and Val473 are observed. Although 
VLB does not bind to the same residues involved with ACh in M5R, its binding energy is 
stronger than that of ACh (-9.28 kJ/mol vs. -4.51 kJ/mol). (Figure 2.9C) 
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Table 2.6: Binding energies of VLB, its metabolites and acetylcholine docked into M5R. 
The energy value for the metabolite with the lowest binding energy is shown in bold. 
M5R ΔGbinding (kJ/mol) 
Acetylcholine -4.51 
VLB -9.28 
MTB1 -11.17 
MTB2 -10.60 
MTB3 -7.88 
MTB4 -7.88 
MTB5 -8.65 
MTB6 -10.04 
MTB7 -5.76 
MTB8 -11.67 
MTB9 -7.32 
MTB10 -6.44 
MTB11 -9.71 
MTB12 -10.05 
MTB13 -15.05 
MTB14 -10.04 
MTB15 -10.79 
MTB16 -11.88 
MTB17 -4.34 
MTB18 -18.68 
MTB19 -12.25 
MTB20 -4.19 
MTB21 -15.33 
MTB22 -18.40 
MTB23 -14.11 
MTB24 -13.63 
MTB25 -15.15 
MTB26 -11.07 
MTB27 -15.31 
MTB28 -8.86 
MTB29 -12.40 
MTB30 -14.84 
MTB31 -12.08 
MTB32 -15.26 
MTB33 -15.13 
MTB34 -17.93 
MTB35 -16.06 
61 
 
2.3.6.3 Metabolites Binding to M5R 
As seen with muscarinic M1 and M4 receptors, many of VLB metabolites bind to the M5 
receptor stronger than ACh, and often interact with the same residues involved with ACh 
binding, such as Tyr480 and Tyr110. (Table 2.4, 2.5 and 2.6) 
The binding energy of metabolite 18 is -18.68 kJ/mol when docked into the binding 
site of M5R. It interacts with residues Asp468, Lys469 and Gln183 through  
H-bonds. The amide group of Gln183 interacts with the carbonyl ester (2.0 Å) and with the 
indole ring (1.7 Å) of metabolite 18. Metabolite 18 also makes hydrophobic interactions 
with Val473 and Trp476. Although metabolite 18 does not interact with exact the same 
residues involved in ACh binding, it binds better than the natural substrate to M5R due to 
its binding energy (-18.68 kJ/mol). (Figure 2.9D) 
 
Figure 2.9: A) Pose view of acetylcholine docked into M5R. Binding interactions of B) 
ACh; C) VLB, and D) Metabolite 18. Hydrogen bonds are shown in dashed lines. 
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Metabolite 23 interacts with the binding site of M5R more than three times stronger than 
ACh (-14.11 kJ/mol and -4.51 kJ/mol) and binds to two of four residues such as Tyr110 
and Tyr480 involved in interactions with the natural substrate. The hydroxyl group makes 
H-bonds with these residues within a distance of 2.5 Å for both interactions. Although the 
distance among residue Tyr110 and metabolite 23 is 0.3 Å longer than the one observed 
with ACh (2.5 Å vs. 2.2 Å), this metabolite has an extra H-bond with residue Thr193 (2.2 
Å, not shown here). Thus, it is suggested that metabolite 23 may induce nausea through 
activation of M5R. (Figure 2.10A) 
Residue Tyr480 which makes an H-bond with the endogenous substrate ACh  
(2.6 Å), makes H-bonds with the hydroxyl group of metabolite 22 within a distance of  
1.9 Å. These interactions are 0.7 Å shorter than the one seen with the substrate (1.9 Å vs. 
2.6 Å). Metabolite 22 has a binding energy of -18.41 kJ/mol docked into M5R, more than 
three times stronger than the binding energy of ACh (-4.51 kJ/mol). Metabolite 22 binds 
to the same residues involved with ACh in the binding pocket of M5R, and can similarly 
trigger the onset of nausea during chemotherapy with VLB. (Figure 2.10B) 
 
Figure 2.10: Binding interactions of A) Metabolite 23 and B) Metabolite 23 docked into 
M5R. Hydrogen bonds are shown in dashed lines.  
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2.3.7 In silico Prediction of Absorption, Distribution, Metabolism, Excretion and 
Toxicology Properties of Vinblastine and its Metabolites 
2.3.7.1 Solubility, Log P and Human Jejunal Effective Permeability  
The gastric solubility (FaSSGF) of VLB is higher than the intestinal solubility in the fasted 
state (FaSSIF) and fed state (FeSSIF) (4.61 mg/mL vs. 4.61 x 10-2 mg/mL and 3.12 x 10-2 
mg/mL, respectively). (Table 2.7) 
A drug possessing a high solubility does not necessarily have a high rate of 
bioavailability that depends on the route of administration and a variety of other 
physicochemical properties such as molecular weight and structural flexibility affecting 
the drug effectiveness [37].  
An orally administered drug must pass through many organs before it reaches the 
blood circulation. On the other hand, IV administered drugs go directly into the blood 
system, and thus achieve 100% of bioavailability. As orally administered drugs, IV 
administered drugs can go to the gut upon absorption and encounter similar pathways to 
be eliminated as well. Thus, IV administered drugs are also able to be reabsorbed in the 
gut or liver and then go back to the blood circulation before excreted through the kidneys 
[38]. In the case of IV administered drugs, only a small amount of the drug in the blood 
flow would be reabsorbed by the stomach, while the main portion of it would go back into 
the intestines [37].  
The human jejunal effective permeability (Peff) of VLB is calculated to be  
0.58 cm/s x 104.  In vivo studies performed by Ogihara et al. [39], have demonstrated that 
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VLB has an intestinal permeability of less than 1.0 x 10-6 cm/s. The authors have also 
shown that VLB is absorbed from the duodenum and ileum, but not from the jejunum in 
the intestinal segments of wild-type mice [39]. Compounds with a Peff lower than  
0.5 cm/s x 104 have low permeability [35]. Although VLB has a Peff higher than  
0.5 cm/s x 104 (0.58 cm/s x 104), it is still considered to be poorly absorbed by the intestines 
as it is administered by IV route. (Table 2.7) 
Metabolite 23 has an intestinal solubility of 3.70 mg/mL in the fasted state 
(FaSSIF). Having the highest intestinal solubility among the metabolites (3.70 mg/mL vs. 
0.01 mg/mL), metabolite 23 is likely to be absorbed back into the blood circulation system. 
However, considering its log P value of 0.22 and Peff through the small intestine  
(0.36 cm/s x 104), metabolite 23 is probably not reabsorbed into the portal circulation in 
the liver. This is because compounds with a Peff less than 0.5 cm/s x 10
4 and a low log P 
(<1) have low permeability and are too hydrophilic to cross the cellular membrane [35].  
(Table 2.7)  
Very hydrophilic compounds with poor membrane permeability (less than  
0.5 x 10-4 cm/s) are more likely to be excreted through the kidneys or remain in the 
intestines rather than be reabsorbed in the blood system [37]. Thus, it is expected that 
metabolite 23 remains in the intestines or is excreted by renal route. If the former is the 
case, metabolite 23 would be able to interact with H1R, M1R, M4R and M5R as these 
receptors are found throughout the body [40]. In addition, metabolite 23 binds to these 
receptors with stronger affinities (-15.13 kJ/mol, -16.86 kJ/mol, -16.63 kJ/mol and  
-14.11 kJ/mol, respectively) than the natural substrates histamine and ACh (-14.40 kJ/mol, 
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-4.79 kJ/mol, -7.65 kJ/mol and -4.51 kJ/mol, respectively). Therefore, due to the ADMET 
findings for metabolite 23 in addition to its likelihood of interaction with nausea associated 
receptors, the metabolite could cause nausea symptoms during chemotherapy with VLB. 
(Tables 2.2, 2.4, 2.5 and 2.6) 
Moreover, metabolite 26, metabolite 29, metabolite 31, metabolite 34 and 
metabolite 35 all have poor intestinal solubility (values close to 0.0 mg/mL) in the fed or 
fasted states (gastric and intestinal). They have high log P (>5.0) and high Peff  
(>0.5 cm/s x 104), with values ranging from 4.93 to 7.04, and 1.08 to 4.73 cm/s x 104, 
respectively. These three parameters (solubility, log P and Peff) can be useful for 
considering whether or not a compound could reach the blood circulation. For instance, 
there is a higher possibility for these metabolites (26, 29, 31, 34 and 35) than metabolite 
23 to cross the intestinal membranes and to be reabsorbed into the blood system due to 
their Peff and log P values. If these metabolites are reabsorbed into the blood system, they 
might account for further off-target interactions with proteins or receptors and cause 
adverse drug reactions. In addition, metabolite 22 and metabolite 34 have a high Peff (1.99 
cm/s x 104 and 2.22 cm/s x 104) compared to the Peff calculated for the other metabolites, 
and have a high likelihood to cross the BBB due to their ability to cross the membrane. 
These are physicochemical properties that facilitate promiscuous off-target binding. In 
addition, metabolite 22 and metabolite 34 display affinities for all nausea associated 
receptors studied in this work (H1R, H3R, D2R, M1R, M4R and M5R), thus have increased 
potential of causing ADRs. (Table 2.7) 
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Table 2.7: Solubility in fed and fasted gastric/intestinal fluids, log P and human jejunal 
effective permeability (Peff) of VLB and its metabolites. 
Drug & 
Metabo-
lites 
Solubility in 
simulated 
fasted state 
gastric fluid 
FaSSGF 
(mg/mL) 
Solubility in 
simulated 
fasted state 
intestinal fluid 
FaSSIF 
(mg/mL) 
Solubility in 
simulated 
fed state 
intestinal 
fluid FeSSIF 
(mg/mL) 
Log P 
Human 
jejunal 
effective 
permeability 
(cm/s x 104) 
VLB 4.61 0.05 0.03 3.95 0.58 
MTB1 12.89 0.14 0.03 3.61 0.53 
MTB2 4.19 0.01 0.03 4.57 0.57 
MTB3 3.94 0.11 0.03 3.26 0.41 
MTB4 3.91 0.10 0.03 3.31 0.43 
MTB5 5.06 0.14 0.03 3.48 0.48 
MTB6 0.43 0.05 0.07 3.73 0.47 
MTB7 3.80 0.08 0.05 3.56 0.46 
MTB8 3.78 0.12 0.05 3.60 0.46 
MTB9 4.16 0.07 0.03 3.81 0.60 
MTB10 4.65 0.11 0.03 2.99 0.43 
MTB11 77.43 0.70 0.08 1.62 0.21 
MTB12 12.76 0.40 0.04 3.12 0.43 
MTB13 2.69 0.17 0.07 3.36 0.42 
MTB14 4.88 0.03 0.03 4.09 0.46 
MTB15 0.31 0.02 0.06 4.34 0.45 
MTB16 2.16 0.02 0.03 4.71 0.84 
MTB17 2.46 0.01 0.02 5.00 0.95 
MTB18 30.79 0.04 0.00 3.99 0.30 
MTB19 35.07 0.15 0.00 3.71 0.30 
MTB20 217.19 0.29 0.30 0.77 0.24 
MTB21 5.79 0.05 0.00 3.96 0.27 
MTB22 3.12 0.90 0.63 2.40 1.99 
MTB23 6.44 3.70 0.57 0.22 0.36 
MTB24 22.01 0.05 0.00 4.50 0.35 
MTB25 26.62 0.07 0.00 4.50 0.38 
MTB26 0.03 0.01 0.07 6.41 3.67 
MTB27 2.56 0.11 0.07 3.93 0.43 
MTB28 183.45 0.15 0.24 1.45 0.27 
MTB29 0.02 0.01 0.02 5.11 1.08 
MTB30 39.10 0.05 0.00 3.92 0.25 
MTB31 0.34 0.07 0.08 4.93 1.44 
MTB32 5.02 0.23 0.08 3.09 0.35 
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MTB33 21.88 0.03 0.00 4.70 0.30 
MTB34 0.48 0.04 0.09 5.69 2.22 
MTB35 0.07 0.01 0.08 7.04 4.73 
 
The predicted ADMET properties of VLB compares to two of the RO5 criteria, as it has a 
log P 3.95 and three HBD groups within the criteria suggested by Lipinski (log P and 
number of HBD groups both <5) [41]. Even though VLB has a desired log P value for a 
drug likeness according to Lipinski’s rules (<5.0), it is poorly absorbed via the oral route 
as mentioned before. This is due to its extensive binding to plasma proteins and to  
P-glycoprotein (P-gp) transporter which are contributing factors to poor oral 
bioavailability. In this case, a drug takes longer to reach its target as it is bound to plasma 
proteins, and once it binds to the cell target, it is effluxed out of the cell by P-gp [37]. 
Therefore, the poor oral bioavailability of VLB may be due to its gastric and intestinal 
solubility, Peff and affinity for both P-gp and plasma proteins. Moreover, VLB has a MW 
of 812.99 g/mol, which ~300 g/mol exceeds the acceptable magnitude according to the 
RO5 and thus influences the low likelihood of oral drug bioavailability [42]. (Tables 2.7 
and 2.8) 
Large and complex molecules similar to VLB also have low membrane 
permeability. Therefore, VLB physicochemical properties do not match to RO5 and thus it 
is reasonable that it is not administered orally. Furthermore, VLB has 12 rotatable bonds 
and a log D value of 3.37 that are in correlation with drug solubility. The RO5 is usually 
followed as a guideline for compounds for oral use, and not intravenously administered as 
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VLB. Many anticancer drugs including VLB were discovered around 1960, and the RO5 
was introduced more than 30 years later, in 1997 [41]. (Table 2.8 and Figure 2.11) 
 
Figure 2.11: Rotatable bonds of VLB. 
2.3.7.2 Volume of distribution, Plasma Proteins, Log D and BBB  
The first possible interaction of VLB and the blood protein human serum albumin (HSA), 
was demonstrated in vitro in 1973 [43], suggesting that the biological effects of the drug 
are increased compared to other anticancer agents with biological effects diminished in the 
presence of albumin [43, 44]. Pandya et al. demonstrated that although VLB was seen 
bound to HSA with an affinity of -7.6 kJ/mol, the binding affinity of the drug for its target 
tubulin was stronger (-10.0 kJ/mol) [45]. The in silico results show that VLB is 89.22% 
bound to plasma proteins due to its hydrophilic character and affinity for these proteins. 
Therefore, only ~10.78% of the drug is in the free form and available to interact with its 
target tubulin. (Table 2.8) 
The Vd of VLB is calculated to be 13.41 L/kg, suggesting that it is highly distributed 
throughout the body. This is in agreement with previous research stating that vinca 
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alkaloids such as VLB have significant Vd [46, 47], that could explain why VLB has a long 
half-life of 35h compared to other anticancer drugs [48] as it is dispersed throughout the 
body, thus taking a long time to be excreted. (Table 2.8) 
Among the metabolites of VLB, metabolite 23 has the highest amount of unbound 
plasma proteins (~77.2%), indicating that the metabolite is more available in the blood 
system than the others. However, it also has a Vd of 0.59 L/kg which indicates that it is not 
scattered throughout the tissues. Although metabolite 23 has a low predicted Peff  
(0.36 cm/s x104), it is known that the less a molecule is bound to the plasma proteins, and 
the smaller it is, the easier can traverse the cell membrane and be considered active to 
interact with protein-receptors [37]. It is noteworthy to point out that this metabolite has a 
low MW (< 400 g/mol) and low affinity for plasma proteins (< 20% bound). As it was 
shown earlier, it has affinity for all nausea associated receptors in this study, and supporting 
the idea that metabolite 23 can induce the onset of nausea during chemotherapy of VLB 
(Tables 2.7 and 2.8) 
Metabolite 11 and metabolite 20 are found in high amounts in the body as their in 
silico predicted values of Vd is calculated as of 0.46 L/Kg and 0.72 L/Kg, respectively. 
However, neither of these metabolites display a significant interaction with any of the 
nausea associated receptors in this study. Therefore, more research needs to be done to 
evaluate other possible interactions during their clearance to identify other off-targets 
receptors. (Table 2.5) 
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Table 2.8: Volume of distribution, percentage of unbound plasma proteins, log D, and log 
BBB coefficient partition of VLB and its metabolites. 
Drug & 
Metabolites 
Volume of 
Distribution Vd 
(L/kg) 
% of unbound to 
plasma proteins  
Log D 
Log BBB 
partition 
coefficient 
VLB 14.02 10.78 3.37 -0.95 
MTB1 11.25 12.23 2.96 -0.89 
MTB2 17.60 7.13 4.08 -0.77 
MTB3 17.65 15.80 2.76 -1.26 
MTB4 17.26 15.06 2.82 -1.40 
MTB5 12.21 13.56 2.91 -1.09 
MTB6 5.55 11.91 3.14 -0.87 
MTB7 2.78 13.13 3.04 -1.16 
MTB8 2.80 13.27 3.04 -1.08 
MTB9 13.59 11.35 3.28 -0.90 
MTB10 12.43 18.83 2.43 -1.29 
MTB11 0.46 46.06 -1.71 -1.43 
MTB12 9.74 15.71 2.48 -1.04 
MTB13 4.34 13.81 2.70 -0.82 
MTB14 15.81 9.09 3.61 -0.93 
MTB15 6.58 8.02 3.83 -0.66 
MTB16 18.81 5.90 4.18 -0.59 
MTB17 13.57 3.00 4.80 -0.80 
MTB18 0.49 11.93 3.25 -1.13 
MTB19 0.36 16.81 1.04 -1.20 
MTB20 0.72 55.70 0.72 -1.10 
MTB21 0.46 13.86 0.78 -0.30 
MTB22 1.67 15.90 1.89 -0.25 
MTB23 0.59 77.22 -0.85 -0.79 
MTB24 0.42 10.45 2.02 -1.02 
MTB25 0.38 9.99 2.16 -1.07 
MTB26 1.53 0.46 6.28 0.16 
MTB27 0.49 9.46 1.31 -0.29 
MTB28 2.95 45.32 1.39 -0.81 
MTB29 1.47 1.12 4.93 -0.45 
MTB30 1.18 15.40 0.80 -0.66 
MTB31 1.58 2.20 4.22 -0.10 
MTB32 0.57 16.59 0.86 -0.68 
MTB33 0.96 9.09 1.62 -0.51 
MTB34 1.43 1.06 5.13 0.17 
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MTB35 1.22 0.60 6.79 0.43 
 
Metabolite 17, metabolite 26, metabolite 29, metabolite 31, metabolite 34 and metabolite 
35 have high affinities for the plasma proteins (< 3% unbound). Even though metabolite 
17 does not have an affinity for M5R (-4.34 kJ/mol vs. -4.51 kJ/mol for ACh), all of the 
aforementioned metabolites have stronger binding energies than ACh for M5R  
(-11.07 kJ/mol, -12.40 kJ/mol, -12.08 kJ/mol, -17.93 kJ/mol and -16.06 kJ/mol vs.  
-4.51 kJ/mol). This is useful to compare the binding affinity of these metabolites against 
the muscarinic receptors and plasma proteins as the former receptors are also present in the 
blood circulation. Therefore, more research is required to investigate the binding profile of 
the aforementioned metabolites with respect to the plasma proteins. (Table 2.6) 
Drugs capable of crossing the blood-brain barrier (BBB) must be lipophilic enough 
to be absorbed by the cell membranes and enter into the brain [37]. The likelihood of VLB 
to cross the BBB is calculated to be log -0.95. VLB has a partial hydrophilic character with 
charged atoms such as the protonated nitrogen atoms at N6ʹ and N9 that make difficult the 
entrance of VLB through the endothelial cells of the central nervous system [49]. 
Therefore, VLB does not cross the BBB. (Table 2.7 and 2.8) 
2.3.7.3 P-glycoprotein and Human ether-à-go-go-related gene 
VLB and its metabolites are all transported by P-gp, whereas a majority of them can also 
inhibit this protein according to the in silico results. The metabolites transported out of the 
cell by P-gp are metabolite 11, metabolite 20, metabolite 22, metabolite 23, metabolite 27, 
metabolite 28 and metabolite 32. Horio et al. have explained that VLB is actively 
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transported by P-gp in Hodgkin’s disease cells (KB cells) with a transport affinity of 2 μM 
for P-gp [50]. Previous studies have shown that VLB is also an inhibitor and inducer of P-
gp [47, 51-53]. This is, VLB is transported out of the cell by P-gp and inhibit the 
functionality of this protein and/or induce its activity to transport other xenobiotics. 
Metabolite 22 and metabolite 23 have a high probability to cross the BBB (-0.25 
and -0.79) and are transported by P-gp. If drugs capable of crossing the BBB are taken in 
concomitantly with VLB, metabolites 22 and 23 are likely to compete with them for 
interaction with P-gp in the brain. If metabolite 22 and metabolite 23 are better binders to 
P-gp than the concomitant drugs, it would be expected an increase of blood concentration 
of either metabolite or of the concomitant drugs in the brain. Therefore, as these 
metabolites are transported out of the cell membrane due to their P-gp affinity, the chances 
of off-targets events and thus drug-drug interactions induced by these compounds are 
increased within the brain environment. (Table 2.8) 
The human ether-à-go-go-related gene receptor (hERG), a potassium channel 
receptor responsible for the action potential of myocardiocytes, is also an important 
enzyme in pharmacokinetic studies due to its cardiotoxicity induced by a drug inhibitory 
effect [54]. Compounds with an inhibitory concentration (IC50) less or equal to 10 μM have 
an affinity for hERG potassium channel and thus block the receptor [35]. In agreement 
with previous research [55], the in silico predicted ADMET data shows that VLB does not 
interact with hERG receptor, but some of its metabolites such as metabolite 19, metabolite 
21, metabolite 27, metabolite 30, metabolite 31, metabolite 32, metabolite 34 and 
metabolite 35 have an affinity to the receptor. Their predicted inhibitory concentration 
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(pIC50) for hERG inhibition is 6.25, 6.07, 6.09, 6.03, 6.18, 6.02, 6.88 and 6.71 mol/L, 
respectively. Therefore, the metabolites aforementioned block hERG channel could cause 
cardiovascular complications post chemotherapy with VLB. Previous research has shown 
that tubulin-binding drugs have a probability to induce cardiotoxicity during cancer 
treatment through damage of endothelial cells of the myocardium, however, the mechanism 
is not yet fully known [56]. Thus, further research is required to evaluate detailed 
mechanism of triggering cardiotoxic events during the clearance of VLB.  
2.3.7.4 Cytochrome P450 complex 
2.3.7.4.1 CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2E1, CYP2C9 and CYP2C19  
As ondansetron, metabolite 22, metabolite 23, metabolite 34 and metabolite 35 are all 
metabolized by CYP1A2. Thus, it is suggested that the binding competition among the 
ondansetron and VLB or its metabolites for CYP1A2 can play a role in determining 
differences in plasma concentration whether used in concomitance during chemotherapy 
[57].  
The predicted ADMET properties show that metabolite 2, metabolite 3, metabolite 
15, metabolite 16, metabolite 17 and metabolite 34 are metabolized by CYP2C8. However, 
neither drug nor metabolites are metabolized by isoforms CYP2A6, CYP2B6, CYP2E1 
and CYP2C19. In addition, metabolite 2, metabolite 15, metabolite 17, metabolite 20, 
metabolite 24, metabolite 25, metabolite 26 and metabolite 27 are able to inhibit CYP2C9, 
whereas only metabolite 35 is metabolized by CYP2C9. Interestingly, metabolite 35 has 
similar chemical structure to the compounds metabolized by CYP2C9 due to the 
heteroatoms and aromatic rings in its molecule [58].  
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2.3.7.4.2 CYP2D6  
The in silico results have shown that VLB and all of its metabolites could inhibit CYP2D6, 
but not all of them are metabolized by this enzyme, this is, they are not substrates (NB) of 
CYP2D6. (Table 2.9) 
VLB and metabolites that are metabolized by CYP2D6 might have drug-drug 
interactions with inhibitors of this enzyme, such as quinidine, cimetidine and ritonavir [59]. 
The concomitant intake of compounds that are metabolized by or inhibit CYP2D6 can 
potentially lead to an increase on the plasma concentration level of VLB. This is due to the 
lower metabolism rate of VLB trigged by enzymatic competition of CYP2D6. For instance, 
if VLB is taken along with the antiarrhythmic agent quinidine, an inhibitor of CYP2D6, 
the plasma concentrations of VLB are increased because CYP2D6 is inhibited by 
quinidine, and thus can cause drug toxicity [60].  
VLB can also cause drug-drug interactions with drugs that are metabolized by 
CYP2D6 [61]. Ondansetron is an antiemetic agent often administered during cancer 
treatment [62]. Because it is metabolized by CYPD26 [63] similar to VLB, ondansetron 
would compete with VLB for metabolism with CYP2D6, thus probably causing drug-drug 
interactions because one of the two compounds would have its plasma concentrations 
increased.  
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Table 2.9: Kinetic and intrinsic parameters (Km, Vmax and CLint) of VLB and its metabolites 
for CYP2D6. 
Drug & 
Metabolites 
Qualitative 
assessment of 
substrates of 2D6 
Kinetic 
Michaelis-
Menten Km 
Kinetic 
Michaelis-
Menten Vmax 
Intrinsic 
clearance (CLint) 
constants  
VLB Yes 1443.0 92.7 0.5 
MTB1 Yes 3949.2 174.6 0.4 
MTB2 Yes 262.0 26.8 0.8 
MTB3 No NB NB NB 
MTB4 No NB NB NB 
MTB5 Yes 5125.5 133.1 0.2 
MTB6 No NB NB NB 
MTB7 Yes 5408.1 170.7 0.3 
MTB8 Yes 5250.9 82.1 0.1 
MTB9 No NB NB NB 
MTB10 No NB NB NB 
MTB11 No NB NB NB 
MTB12 Yes 10276.2 265.2 0.2 
MTB13 Yes 2502.8 232.8 0.7 
MTB14 Yes 1714.9 67.4 0.3 
MTB15 No NB NB NB 
MTB16 Yes 246.1 17.6 0.6 
MTB17 No NB NB NB 
MTB18 No NB NB NB 
MTB19 No NB NB NB 
MTB20 No NB NB NB 
MTB21 Yes 6.5 18.9 23.4 
MTB22 Yes 89.9 32.7 2.9 
MTB23 Yes 15.1 10.4 5.5 
MTB24 No NB NB NB 
MTB25 No NB NB NB 
MTB26 Yes 3.5 24.8 57.3 
MTB27 No NB NB NB 
MTB28 Yes 137.1 29.8 1.7 
MTB29 Yes 20.9 47.7 18.2 
MTB30 No NB NB NB 
MTB31 Yes 31.1 48.8 12.6 
MTB32 No NB NB NB 
MTB33 Yes 0.9 33.3 295.3 
MTB34 Yes 24.6 13.0 4.2 
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MTB35 Yes 2.9 9.8 27.4 
*Km (μM). Vmax (nmol/min-1/nmol-1). CLint(μL/min/mg HLM protein), HLM: human liver 
microsomes (concentration of 0.5 mg/mL). NB: non substrate.  
 
CYP3A4 plays the major role in the metabolism of VLB and its metabolites. Some VLB 
metabolites that are metabolized by both CYP3A4 and CYP2D6, such as metabolite 1, 
metabolite 2, metabolite 5, metabolite 7, metabolite 13 and metabolite 14. As these 
metabolites are preferentially bound to CYP3A4, they would interfere with the metabolism 
of the drugs binding to CYP3A4 whether other drug is taken in concomitance. (Tables 2.9 
and 2.10) 
2.3.7.4.3 CYP3A4 
According to the in silico predictions, the metabolism of VLB and all of its metabolites is 
mediated by CYP3A4. However, the activity of CYP3A4 is also inhibited by all of them. 
(Table 2.10)  
This is in agreement with the in vitro PK study of VLB that has shown that VLB is 
both a substrate [47, 64, 65], and an inhibitor of CYP3A4 [64, 66], which is the same 
observed for its metabolites. Levêque and Jehl have revised the PK of the main vinca 
alkaloids used to treat cancer and shown that VLB is highly metabolized by CYP3A4 in 
human liver microsomes [47]. In addition, Zhou-Pan et al. have demonstrated that the Km 
and Vmax constants of VLB are 6.82 ± 0.27 μM and 0.64 ± 0.06 nmol/min/mg P450, 
respectively [64]. The inhibitory effect of CYP3A4 caused by VLB was investigated by 
Baumhäkel et al., which has shown that the IC50 of VLB was 20 and 44 μmol/L in two 
human liver microsome samples compared with the plasma concentrations of 
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antineoplastic drugs taken during chemotherapy [66]. Both inhibition of or metabolism by 
CYP3A4 is an important factor to explain treatment failures commonly seen with VLB as 
well as adverse drug reactions caused by drug-drug interactions whether co-administered 
with other drugs. (Table 2.7) 
VLB has a Michaelis-Menten constant (Km) of 19.9 μM and a maximum metabolic 
rate (Vmax) of 25.2 nmol/min
-1/nmol-1 P450. Even though it is also a substrate of CYP2D6, 
another important enzyme in drug metabolism, VLB has much higher Km for CYP2D6 
(1443.0 μM) than for CYP3A4 (19.9 μM), thus indicates a significant affinity for the latter 
enzyme. (Table 2.9 and 2.10) 
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Table 2.10: Kinetic and intrinsic parameters (Km, Vmax and CLint) of VLB and its 
metabolites for CYP3A4. 
Drug & 
Metabolites 
Kinetic Michaelis-
Menten Km 
Kinetic Michaelis-
Menten Vmax 
Intrinsic clearance 
(CLint) constants  
VLB 19.9 25.2 299.1 
MTB1 17.5 13.2 183.6 
MTB2 26.3 24.8 345.0 
MTB3 17.3 25.0 109.5 
MTB4 14.8 26.7 82.1 
MTB5 21.6 25.0 134.7 
MTB6 21.8 23.1 239.7 
MTB7 17.8 11.2 144.8 
MTB8 18.9 12.9 154.8 
MTB9 16.8 9.3 333.2 
MTB10 17.6 27.7 140.0 
MTB11 64.5 7.2 139.4 
MTB12 19.4 13.3 75.2 
MTB13 19.5 15.8 146.9 
MTB14 30.0 25.3 156.9 
MTB15 28.9 21.3 282.1 
MTB16 32.8 76.8 327.3 
MTB17 6.6 12.7 1107.9 
MTB18 13.2 2.3 1871.7 
MTB19 21.3 3.7 993.2 
MTB20 28.7 6.4 183.2 
MTB21 17.4 2.8 1781.9 
MTB22 192.5 36.4 11.0 
MTB23 326.2 3.8 19.5 
MTB24 23.3 1.8 1614.7 
MTB25 22.4 2.2 1952.1 
MTB26 6.2 2.5 556.5 
MTB27 67.0 0.7 503.9 
MTB28 25.8 4.1 498.5 
MTB29 6.3 3.1 149.2 
MTB30 22.0 3.5 3507.8 
MTB31 31.1 10.1 93.4 
MTB32 72.8 1.4 187.9 
MTB33 23.4 2.0 6361.0 
MTB34 28.5 8.1 132.3 
MTB35 11.4 1.8 592.5 
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*Km (μM). Vmax (nmol/min-1/nmol-1). CLint(μL/min/mg HLM protein), HLM: human liver 
microsomes (concentration of 0.5 mg/mL). NB: non substrate.  
 
2.3.7.5 Phase II Metabolism - Glucuronidation Reactions 
VLB and its metabolites were screened against Uridine 5ʹ-Diphosphate-
Glucuronosyltransferase (UGT), an enzyme responsible for catalyzing glucuronidation 
reaction during Phase II drug metabolism [67]. In particular, the UGT isoforms UGT1A1, 
UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15 
were experimentally tested for VLB and metabolites in this work. The in silico data shows 
that VLB is not catalyzed by any of the UGT enzymes indicating that VLB is not 
conjugated through glucuronidation metabolism. This correlates with Owellen et al. 
results, that demonstrated VLB does not undergo glucuronide neither sulfate formation 
[68]. However, some of the metabolites undergo glucuronidation reactions with enzymes 
UGT1A3, UGT1A8 and UGT2B7 while the remaining metabolites do not undergo 
glucuronidation. (Table 2.11) 
Table 2.11: Phase II of metabolites of VLB with isoenzymes UGT1A3, UGT1A8 and 
UGT2B7. 
Qualitative model of 
glucuronidation by 
UGT1A3 
Qualitative model of 
glucuronidation by 
UGT1A8 
Qualitative model of 
glucuronidation by 
UGT2B7 
MTB9 (45%)  
MTB26 (49%) 
MTB27 (49%) 
MTB32 (47%) 
MTB19 
MTB22 (61%) 
MTB23 (65%) 
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2.4 Conclusion 
VLB and its metabolites were docked into nausea associated receptors D2, H1, H3, M1, M4 
and M5 by means of molecular docking and their binding interactions were compared to 
that of dopamine, histamine and acetylcholine. Furthermore, the ADMET properties of 
VLB and its metabolites were predicted through in silico experiments. The potential for 
VLB and its metabolites to interact with receptors involved in nausea induced by 
chemotherapy was evaluated. The results have shown that VLB plays a role in the M5R, 
and it might compete with histamine for the binding site of H3R. On the other hand, the 
metabolites of VLB bind to all of the nausea associated receptors used in this study, and 
thus can trigger nausea during chemotherapy with VLB. The molecular docking has shown 
that the metabolites of VLB have binding affinities mainly for the muscarinic receptors 
along with similar binding interactions to that of ACh in the binding site of the target 
receptor.  
In the binding pocket of M1R, metabolite 22 and metabolite 23 interact with the 
same residues involved in the binding of ACh, such as Tyr106, Tyr404 and Tyr381. For 
instance, metabolite 23 makes stronger H-bonds with residues Tyr104 and Tyr404 than 
ACh (1.7 Å and 1.6 Å vs. 2.4 Å and 2.2 Å, respectively). Furthermore, metabolite 22 and 
metabolite 23 have both binding affinities stronger than that of ACh (-18.24 kJ/mol and  
-16.84 kJ/mol vs. -4.79 kJ/mol). Thus, it is evident that these metabolites display significant 
binding interactions with the binding pocket of M1R, and could be involved in the onset of 
nausea through receptor activation.  (Table 2.4) 
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The metabolites of VLB also display binding affinities for M4R and thus may be 
involved with nausea during chemotherapy with VLB through this additional receptor. For 
instance, Tyr439 and Tyr113 of ACh binding site in the M4R, also interact with metabolite 
13, metabolite 19, metabolite 18, metabolite 34, metabolite 22, metabolite 23 and 
metabolite 10 by either hydrophobic contacts or H-bonds. Metabolite 13 has a binding 
energy of -20.65 kJ/mol, more than twice of ACh (-7.65 kJ/mol). Although it does not 
interact with any of the residues directly interacting with ACh, it can compete with the 
natural substrate for stronger interactions with M4R. Moreover, metabolite 23 and 
metabolite 10 both have the same type of interactions as ACh and interact with the same 
residues in M4R. For instance, metabolite 23 and metabolite 10 interact with residue 
Tyr439 within a distance of 1.6 Å and 1.8 Å, respectively, compared to 3.0 Å for ACh. 
Besides that, metabolites 23 and 10 (-16.63 kJ/mol and -10.16 kJ/mol) have stronger 
affinities than ACh (-7.65 kJ/mol) for M4R, hence compete with ACh for activation of 
M4R. Therefore, the in silico results have shown that the metabolites of VLB are likely to 
contribute to nausea through activation of M4R, as well. (Table 2.5) 
In respect to M5R, metabolite 18, metabolite 22 and metabolite 23 have better 
binding affinities for the binding pocket of the receptor than the substrate. Residues 
Tyr110, Tyr480 and Tyr457 are involved in the binding of ACh to M5R, whereas only 
Tyr110 and Tyr480 make H-bonds with the substrate. Metabolite 22 and metabolite 23 
make H-bonds and hydrophobic interactions with all of the residues involved with ACh. 
For instance, metabolite 22 (1.9 Å) and metabolite 23 (2.5 Å) interact with residue Tyr480 
in closer proximity than the substrate (2.6 Å), and both have binding affinities for M5R  
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(-18.40 kJ/mol and -14.11 kJ/mol, respectively, vs. -4.51 kJ/mol for ACh). Furthermore, 
metabolite 23 also make a H-bond with Tyr110 within a distance of 2.5 Å, which is  
0.3 Å longer than that of ACh (2.2 Å). However, it has an additional H-bond with residue 
Thr193, favoring its interaction with the receptor. Therefore, all of the aforementioned 
metabolites have binding affinities for M5R and could compete with ACh for the binding 
to M5R. Thus, it is evident that the metabolites of VLB such as metabolite 22 and 
metabolite 23 affect the function of M5R during chemotherapy with VLB and could play a 
role in the development of nausea. (Table 2.6) 
The ADMET results for VLB and metabolites have shown that all of them are 
inhibitors of CYP2D6 and CYP3A4. They could be metabolized by CYP3A4 and 
transported out of the cell by P-gp as well. This could explain why drug-drug interactions 
are seen with VLB when a variety of drugs are taken in concomitance. In addition, drugs 
that are metabolized by, or inhibit CYP2C8 and/or CYP2C9, and are taken concurrently 
with VLB, also account for drug-drug interactions during chemotherapy with VLB. This 
is because the metabolites of VLB can also be metabolized by or inhibit these two 
isoenzymes, thus an enzymatic competition is likely to occur. (Tables 2.9 and 2.10) 
Among the VLB metabolites, metabolite 23 interacts well with nausea associated 
receptors. Its PK properties are of extremely importance for evaluation of how this 
metabolite behaves inside the body. It has an intestinal solubility (FaSSIF) of 3.70 mg/mL, 
and an affinity for plasma proteins with 77.2% of it unbound, therefore indicates its 
availability for off-targets binding. (Tables 2.7 and 2.8) 
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Moreover, the predicted results demonstrate that only a few metabolites of VLB 
undergo phase II metabolism through UGT. It is noteworthy that metabolite 22 and 
metabolite 23, which display strong binding affinities and similar binding profile to the 
substrates for all nausea associated receptors, can undergo glucuronidation through 
catalysis of UGT2B7. Therefore, their effect within the body must be investigated due to 
the fact that glucuronidation reaction can also cause toxicity [67]. In addition, a few 
metabolites of VLB block hERG receptor involved in cardiotoxic events and can cross the 
BBB, thus further investigation on the effects of these metabolites in different organ tissues 
is needed. (Table 2.11) 
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CHAPTER 3 Effects of Vinblastine and its Metabolites on Alopecia 
Associated Receptors 
3.1 Introduction 
3.1.1 Chemotherapy-Induced Alopecia 
Chemotherapy-induced alopecia (CIA) remains one of the most unpleasant side effects 
during cancer treatment. The hair follicle (HF) is an unwanted target for anticancer drugs 
to affect, due to the fact that their matrix keratinocytes division rate can be higher than that 
of the neoplastic cells [1]. The occurrence of CIA is seen in 65% of the patients and depends 
on various factors. CIA leads to both psycho and physiological distress in patients with 
cancer. According to Patel et al., around 50% of patients consider hair loss as the most 
traumatic experience during chemotherapy, and 8% of them would deny receiving 
chemotherapy [2]. Hair loss can begin anytime during chemotherapy, from days to a few 
weeks. Depending on the drug and therapy schedule, alopecia can occur during treatment 
or several weeks after the start of the first treatment and can progress gradually for 1 to 2 
months [3-6]. The regrowth of hair usually occurs from 1 to 6 months after chemotherapy. 
Even though rare, permanent CIA is becoming more reported due to injury of the bulge 
and bulb hair, where stem cells are located. CIA can also affect the melanocytes, which 
can change the pigmentation color of the HF and its shape. Thus the hair can become either 
gray and/or curly after chemotherapy [7].  
CIA can occur in more than 80% of the patients undergoing treatment with vinca 
alkaloids drugs and/or antimicrotubule agents. VLB is known to cause alopecia in cancer 
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patients [1, 5]. Interestingly, whilst VLB was under preliminary clinical trials, a study 
conducted by Crounse and Scott showed that it caused severe alopecia in treated-patient, 
in addition to the oral ulceration and myelosuppression [8].  
Currently, the most effective treatment and/or prevention of alopecia during 
chemotherapy is the scalp cooling device. The cold cap constricts blood vessels and 
interrupts chemotherapeutic agent circulation in the scalp due to the low temperature 
setting. Some patients have headaches as a secondary effect when using the cold cap which 
is called brain freeze [9]. The rate of its effectiveness ranges from 50-80%. Despite 
advances with targeted therapies and radiotherapy, chemotherapy is still widely used and 
the scalp cooling device to reduce alopecia is not well received by most of patients going 
through the treatment [2, 10].  
The amount of hair loss depends on the drug, dosage and route of administration. 
For instance, radiotherapy is delivered to a specific area and may cause hair loss only in 
the area receiving the treatment. In addition, hormonal therapy does not usually cause 
complete hair loss. Apart from the scalp cooling device, there are a variety of treatment 
options to alleviate or prevent alopecia during chemotherapy, but none of them have 
demonstrated significant success. Rubio-Gonzalez et al. have reviewed the most recent 
therapeutic approaches for CIA that include non-approved topical formulations of 
minoxidil, calcitriol, bimatoprost and others [5]. Similar to minoxidil, also spironolactone 
and finasteride may help the hair to regrow [2, 5]. CIA is defined as a diffuse nonscarring 
alopecia because it slowly reduces the hair growth and maintains the follicular ostia, where 
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the hair fibers grows from the skin. Alopecia caused by VLB can take up to 6 months for 
complete hair recovery [5].  
Advances in the health care field to treat or prevent alopecia during chemotherapy 
include drug interventions and the use of an appropriate medical device system. However, 
physicochemical properties of the chemotherapeutic agents, which are the main cause of 
hair loss during cancer therapy, are yet to be studied.  
3.1.2 Hair Follicle Cycle 
Regulation of the hair cycle is obtained by the interchangeable interactions between the 
epithelial keratinocytes and the dermal papilla. The hair cycle is divided into three main 
phases known as anagen (growing), catagen (involution), and telogen (rest). During life, 
the keratinocytes or the proliferating matrix cells of the majority of HF are in the anagen 
phase (80-90%), while 5-10% are in the telogen phase and 1-3% in the catagen [5, 11]. The 
transition order of phases in the hair cycle occurs as anagen-to-catagen, catagen-to-telogen 
and telogen-to-anagen. The first phase is responsible to induce HF apoptosis when it is 
necessary in the natural cycle. Death of HF is a normal maintenance process of the hair 
cycle, but it can also be early induced during treatment of xenobiotics that target the 
proliferating matrix cells or the dermal papilla. The telogen-to-anagen transition phase 
causes the HF to exit quiescence or resting state, and to regrow again. These important HF 
transition states must be well coordinated and controlled to maintain cell survival and hair 
optimal conditions. An anagen cycle can last for many years, while the other two HF states 
last for a few days or months [12]. Different from mammals, human hair follows an 
asynchronous growth pattern. This miscellaneous or so-called mosaic pattern is 
95 
 
characterized by an independent HF growth, which no individual HF follows its neighbor 
hair cycle [13].  
Signaling molecules such as bone morphogenic protein (BMP), Wingless (Wnt) 
and Hedgehog (Hh) are involved in the anagen onset pathway during embryonic and 
postnatal life cycles [7, 12]. The initiation process of the hair cycle occurs after nearly one 
month from the time a HF is in the telogen phase. The levels of Wnt antagonists such as 
Dickkopf (DKK1) and Secreted Frizzled-Related Protein 4 (SFRP4), as well as the levels 
of BMP2/4 signaling molecules, are decreased during the initiation of a hair cycle. The low 
expression of these antagonist ligands leads to the activation of Wnt signaling pathway, 
initiating anagen phase and hair growth. Another signaling molecule that positively 
controls the telogen-to-anagen phase is the fibroblast growth factor (FGF) 18, which is 
known to function as an antiproliferative protein that prolongs the duration of the HF in 
the refractivity telogen period. The deletion of FGF18 shortens the refractivity period of 
telogen by one week instead of one month, thus it normally works as a telogen inhibitory 
factor. In addition, overexpression of Noggin, an antagonist of BMP, reduces activity of 
BMP, thus initiates anagen more quickly. Another regulator of BMP during refractivity 
telogen phase is the transforming growth factor (TGF-β2) mediated via paracrine signaling 
during initiation of anagen [12]. Therefore, BMP signaling pathway must be inhibited 
during initiation of a hair cycle. Moreover, signaling molecules such as Notch proteins, 
sonic hedgehog (Shh), epidermal growth factor (EGF) and tumor necrosis factor (TNF) are 
also involved in the control of hair cycle [1, 5]. (Figure 3.1 and Table 3.1). 
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3.1.3 The Hair Follicle on the Chemotherapy-Induced Alopecia 
Chemotherapeutic agents likely damage the hair bulb of the anagen hair follicle. This is an 
area where the proliferative matrix of keranoticytes responsible for the formation of hair 
shaft and inner root sheath are located. Thus, anticancer drugs disturb the active growing 
of the hair follicle, interrupt the normal hair cycle and induce alopecia. The hair can regrow 
because the region of the arrector pilli muscle where the epithelial stem cells are located 
(i.e. bulge region) is not usually targeted by the anticancer drugs. If this area is affected,  
loss of stem cells interrupts formation of a new hair follicle [4]. 
Each HF follows its own full cycle, without any synchronized growing. However, 
as most of the HF are in the anagen phase (80-90%), CIA is often referred to as dystrophic 
anagen effluvium [3, 5]. Thus anagen HF and their pigmentary system are the main targets 
during chemotherapy. The melanocytes produces lots of melanin during anagen phase that 
are transferred to the keratinocyte populations to form the hair-shaft. The HF vasculature 
and sebaceous gland also are affected by chemotherapy, and probably that occurs to the 
mesenchyme, too. Apparently, the anagen HF have mechanisms to self-repair and resist 
against damage during chemotherapy such as an increase in proliferative activity to 
overcome the HF injury. This explains why some patients do not experience baldness and 
for those who have alopecia, once the treatment is completed, the hair grows back to normal 
again [4]. CIA is irreversible only after treatment with busulfan chemotherapy and bone 
marrow transplantation. Dystrophic anagen effluvium is induced by vinca alkaloids where 
the amount of hair loss depends on the dose, route and schedule [2].  
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During chemotherapy, there are two main pathways by which alopecia can be 
induced, the dystrophic anagen and the dystrophic catagen. The former is defined as a less 
severe follicular damage where the pigmented hair shaft changes and the HF undergoes 
two recovery phases, thus it is considered a long recovery process. The latter causes a more 
severe damage, with no pigmentation changes and a short recovery process [4]. Paus et al. 
have demonstrated that the CIA of cyclophosphamide-treated mice results from a 
dystrophic catagen alopecia with shortened telogen phase, but more severe damage of the 
HF is observed [14]. Total hair loss generally occurs in the frontal and occipital hairlines. 
The alopecia induced by chemotherapy is usually reversible, but it depends on the degree 
of the damage in epithelial hair follicle stem-cell. Besides all the undesired side effects 
caused by chemotherapy such as nausea, fatigue, myelosuppression, etc. [15], the 
psychological stress behind this condition is considered a relevant reason for the inhibition 
of hair growth/maintenance. Physiological stress is highly associated with the release of 
inflammatory mediators such as corticotropin-releasing hormone, substance P, an 
undecapeptide, and nerve growth factor. These mediators inhibit hair growth of follicles 
and promote catagen phase development followed by telogen effluvium [4].  
Drugs are known to induce hair loss by different mechanisms such as the telogen 
effluvium, anagen arrest, and accentuation of androgenetic alopecia by androgens [2]. If 
drugs cause telogen effluvium or anagen arrest, the HF undergoes an early and unexpected 
entrance to the catagen phase that leads to hair loss. This early transition to the catagen 
phase is the direct accumulation of any xenobiotic on the HF cells during the anagen phase. 
This effect then leads to the interruption of mitotic activity, known to induce the HF to 
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entry the catagen phase. The hair fiber is hence broken because the growing hair shaft is 
only partially keratinized [4, 5].   
CIA is believed to cause toxicity to both the proliferative matrix keratinocytes cells 
and the follicular pigmentary system of the HF. This off-target event causes acceleration 
in the transition of anagen-to-catagen of the HF [5-7]. The HF that enters early dystrophic 
catagen state undergoes uncontrolled apoptosis, thus compromising the integrity of the hair 
shaft and eventually making the hair to break and fall out. The specific molecular 
mechanisms of the HF that are either activated or inhibited during chemotherapy remain 
largely unknown. Paus et al. have elucidated the pathobiology involved in CIA, and how 
DNA damage caused by chemotherapeutic drugs leads to apoptosis, cell-cycle arrest and/or 
senescence, and thus alopecia [4].  
Hussein et al. have introduced the first mouse model undergoing chemotherapy 
with cyclophosphamide, which has shown that keratinocytes of the outer and inner root 
sheaths, as well as melanocytes have abnormal excessive death of First Apoptosis Signal 
Receptor (FAS) and p55TNFR [16]. Furthermore, an upregulation of pro-apoptotic protein, 
Bcl-2-lymphoma-like protein 4 (BAX), in the HF and uncoordinated apoptosis have been 
demonstrated [16, 17]. Transcriptional factor p53 mediates DNA damage responses and 
involves upregulation of BAX and β-cell lymphoma 2 (BCL-2) proteins. It predisposes the 
HF cells to apoptosis either in normal conditions or during chemotherapy. In mice model 
with p53 deficient, neither apoptosis nor hair loss were observed in the keratinocytes matrix 
after chemotherapy [17]. P21 is a p53 target gene that is upregulated during DNA damage. 
Accumulation of p21 leads to binding and inactivation of Cyclin-Dependent Kinase 2 
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(CDK2)/cycling E complex, resulting in G1/S phase inhibition. P21 is not found in hair 
keratinocytes, however, CDK2 inhibitors have shown reduced hair loss induced by 
chemotherapy. In addition, p53 inhibitors may suppress hair loss during chemotherapy 
[17]. Therefore, it is well known that the HF undergo apoptosis during chemotherapy due 
to the activation of p53 transcription factor [3, 4, 7, 18, 19]. A study of cyclophosphamide-
treated mice has shown that proteins involved in the p53 signaling pathway, such as pro-
apoptotic BAX and anti-apoptotic Bcl-2, have increased and decreased expression levels, 
respectively [20]. Moreover, FAS and c-Kit proteins, involved in the p53 cycle activation, 
have been also shown to induce HF apoptosis induced by chemotherapy [21]. Inhibition of 
p53 through MDM2 controller, a negative regulator of p53, promotes HF survival after 
chemotherapy, indicating that apoptosis through activation of MDM2-p53 complex is 
indeed a mechanism that results in HF lost [4]. 
Hair-bulb melanocytes affected by chemotherapy can either express FAS that 
induces apoptosis, or c-Kit receptor that sends signals to proliferative cells to migrate 
towards the epidermis. The latter causes shrinkage of the hair and indicates a negative 
effect induced by FAS and c-Kit. However, studies have shown that c-Kit neutralizing 
antibody can avoid shrinkage of the hair, thus working as a positive regulator of the HF 
[4]. 
In normal hair cycle, the induction of apoptosis is the transition anagen-to-catagen 
is triggered by a variety of molecules such as FGF7, Interferon (IFN)-γ, substance P, 
estrogens; etc. [1]. Molecules identified during apoptosis and induced by chemotherapy 
include FGF7, ABC transporters, vitamin D receptor (VDR), parathyroid hormone (PTH), 
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EGF receptor (EGFR), and cyclin-dependent kinase 2 (CDK2) [4, 7]. Skrok et al. have 
thoroughly illustrated the proteins and their signaling pathways expressed in the HF and 
also those which have been postulated as modulators of the hair cycle [22]. Several proteins 
have been identified being activated or inhibited during CIA, depending on their own 
normal function in the HF. Important pathways responsible for the hair development, 
differentiation, proliferation and cycle which are unregulated during chemotherapy include 
Wnt/β-catenin, Shh, Notch and BMP/Noggin signaling. Additionally, a great variety of 
protein receptors involved in hormone regulation and apoptosis are expected to participate 
during CIA process [5, 22]. CIA is a complex mechanistic adverse effect that requires 
further in-depth investigation of its relevant signaling pathways. (Figure 3.1 and Table 
3.1) 
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Table 3.1: Main signaling pathways involved in the development, differentiation, 
proliferation and maintenance of the HF and their receptor, ligand, location in the HF, 
likelihood of activated or inhibited states as well as their PDB entry. 
 
Protein 
Signaling 
Ligand 
Location in 
the HF 
Normal role 
in the HF 
In 
CIA 
PDB 
entry 
Ref. 
H
a
ir
 F
o
ll
ic
le
 C
o
n
tr
o
l 
Wnt Frizzled 
Outer root 
sheath 
Development, 
proliferation, 
differentiation 
- 3S2K 
[23, 
24] 
Shh 
(SMO) 
Cyclo-
pamine 
LY2940680 
Anta XV 
Dermal 
papilla 
Development, 
proliferation, 
differentiation 
- 
4O9R 
4JKV 
4QIM 
[11, 
25-
27] 
Notch 
Jagged1/2DL
L1/3/4 
Proliferating 
matrix, 
outer root 
sheath 
Development, 
proliferation, 
differentiation 
- 4XBM 
[28, 
29] 
BMP Noggin 
Dermal 
papilla 
Development, 
proliferation, 
differentiation 
+ 1M4U [11] 
H
o
rm
o
n
es
-R
el
a
te
d
 
PTH1R 
PTH 
PTHrP 
Dermal 
sheath and 
papilla 
Proliferation, 
differentiation 
+ 
3C4M 
3H3G 
[22, 
30] 
Vitamin D 
Receptor 
Calci-triol 
TEI-9647 
Dermal 
papilla and 
outer root 
sheath 
Anagen 
initiation and 
differentiation 
- 
1DB1 
3A2J 
[31] 
FGFR1 FGF5 
Dermal 
papilla 
Induces 
anagen-to-
catagen 
+  [32] 
FGFR FGF7 
Dermal 
papilla, 
keratinocyte
s 
Inhibits free 
radicals to 
induce 
apoptosis 
-  
[4, 
33, 
34] 
Androgen 
Receptor 
Testos-terone 
DHT 
Bicalu-
tamide 
Dermal 
papilla 
Inhibits 
Wnt/β-catenin 
pathway 
+ 
2AM9 
2AMA 
1Z95 
[35] 
EGFR EGF Hair matrix 
Up-regulates 
p53 
+  [36] 
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l 
ABC 
Transp. 
 
Outer root 
sheath of 
the lower 
isthmus 
(insertion of 
arrector pili 
muscle) 
Use energy 
from ATP 
hydrolysis to 
move 
substrates 
from the cell. 
May protect 
HF 
keratinocytes 
- 6C0V [4] 
FAS FASL 
Hair matrix, 
melanocytes
; outer and 
inner root 
sheath 
Apoptosis 
(pro-
apoptotic) 
+ 
4MSV 
3TJE 
[1, 4, 
37] 
p53 MDM2 
Hair matrix; 
outer root 
sheath 
MDM2 forms 
a complex 
with p53. If 
apoptosis is 
required, 
MDM2 is 
inhibited and 
p53 gets free 
+ 1YCR [1, 4] 
MDM2 Nutlins 
Hair matrix; 
outer root 
sheath 
Inhibition of 
MDM2 leads 
to p53 
activation 
hence 
apoptosis 
- 1RV1 [38] 
BAX  Hair matrix; 
Apoptosis 
(pro-
apoptotic) 
+  [1, 4] 
BCL-2  
Melanocyte
s; hair 
matrix; 
dermal 
papilla 
Anti-apoptotic -  [1, 4] 
CDK2 
Cyclin A 
Stauros-
porine 
Post-mitotic 
keratinocyte
s 
Stimulates 
cell-cycle 
arrest 
+ 
1FIN 
1AQ1 
[4, 
37, 
39] 
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Figure 3.1: Signaling pathways involved in the development, proliferation and 
maintenance of the adult hair follicle.  
 
3.1.4 Signaling Molecules Involved in Chemotherapy-Induced Alopecia 
3.1.4.1 Hormones-Related 
3.1.4.1.1 Testosterone 
Testosterone is a steroid hormone that mainly contributes to the male reproductive system 
development, but it is also secreted by the ovaries. It binds and activates androgen receptor 
(AR), that among a great diversity of functions, regulates the skin physiology and the HF 
development. It is suggested that AR activation leads to inhibition of Wnt/β-catenin 
signaling in murine HF, thus negatively controlling the hair cycle pathway. However, the 
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exact mechanism by which activation of AR inhibits hair growth remains to be elucidated 
[35, 40].  
One of the proposed mechanism of AR inducing catagen in the HF it that expression 
of 5α-dihydroxytestosterone (DHT), a metabolite of testosterone, in the dermal papillae 
leads to an increase of interleukin (IL) 6 and glycoprotein 130 expression. These molecules 
are known to be involved in the transition of anagen-to-catagen [22]. DHT is a stronger 
activator of AR than testosterone and indirectly inhibits the matrix cell proliferation leading 
to hair shaft shortening [11]. (Table 3.1) 
The AR is classified as a nuclear receptor superfamily as it posses a N-terminal 
domain (NTD), a conserved DNA-binding domain (DBD) and more importantly, a ligand-
binding domain (LBD), where testosterone or DHT bind to. It is known that the binding 
site of AR is highly hydrophobic and that the LBD adopts a sandwich α-helical 
conformation, a known feature of nuclear receptors. Despite the polar residues at the 
extremities of the binding pocket, the recognition of AR is mediated by hydrophobic 
residues that confers selectivity and stability of the substrate. The AR structure is 
comprised of 11 α-helices and 4 β-strands, whereas residues of helices H3, H4, H5, H11 
and β-strand among H5 and H6 comprise the flexible LBD. One essential residue required 
for activation of AR is Arg752 that makes a H-bond with the ketone group of androgen 
ligands [41]. The natural substrates of AR, testosterone and DHT both have four cycles 
named A, B, C and D. These steroid-based structures have a ketone at position C3 and a 
hydroxyl group at position 17β in cycle D (cyclopentanol), respectively. They only differ 
by a cyclohexanone present at cycle A of testosterone. This structural difference among 
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testosterone and DHT changes the orientation of the ketone group at C3 of DHT, increasing 
its strength in the binding interaction with residue Arg752 [41]. (Figure 3.2) 
 
Figure 3.2: Chemical structures of the endogenous substrates of androgen receptor. A) 
Testosterone and B) DHT. 
 
3.1.4.1.2 Prostaglandins  
Prostaglandin (PG) subtype D2 (PGD2) and its metabolite 15-deoxy-Δ(12,14)-
prostaglandin J2 (15-dPGJ2) have been shown to be involved in HF growth inhibition. 
High concentrations of 15-dPGJ2 in human HF cultured cells are induces apoptosis in HF 
and cause alopecia [42]. Upregulation of PGD2 which is synthesized through an enzyme 
mechanism induced by testosterone has been suggested to be involved in androgenetic 
alopecia. This signaling pathway could be activated during chemotherapy, however, this 
hypothesis has not been confirmed [43]. Interestingly, during chemotherapy there is an 
increase in the expression of cyclooxygenase-2 (COX-2) that induces synthesis of PGs, 
especially prostaglandin E2, suggesting its possible role during alopecia [44]. However, the 
mechanism by which either PGD2 or PGE2 can dysregulate the hair cycle is still unclear. 
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3.1.4.1.3 Parathyroid   
Parathyroid hormone (PTH) is considered an inhibitor of hair development. PTH has been 
shown to function as an inducer of anagen-to-catagen transition phase in the HF [22, 30]. 
As a response of low levels of calcium, PTH is synthesized to promote calcium 
reabsorption in the kidneys and to synthesize 1,25-dihydroxyvitamin D3 [45]. Also a 
polypeptide, the PTH related protein (PTHrP) shares 70% homology with the N-terminal 
of PTH. Both molecules and their receptor, the parathyroid hormone receptor (PTH1R) are 
all expressed in the hair, mainly in the dermal sheath and dermal papilla. It seems that the 
activation of PTH1R leads to induction of the anagen-to-catagen transition on the HF [22, 
30]. 
The mechanism by which activation of PTH1R is suggested to be involved in CIA 
requires at least the binding of PTH or any other agonist in the transmembrane (7TM) of 
the receptor. However, the specific residues of PTH1R responsible for the PTH/PTHrP 
interaction hence induction of activation remain to be elucidated. Shimizu et al. have 
reported that PTH lacks the C-terminal fragment (15-34) and with the N-terminal modified 
is able to antagonize the receptor [46]. However, there is no further details about which N-
terminal modifications are required for PTH1R antagonism effect, neither how the binding 
interactions take place. (Table 3.1) 
3.1.4.1.4 Vitamin D 
Vitamin D receptor (VDR) regulates the levels of calcium and phosphate that are 
responsible for bone development and maintenance. When vitamin D is synthesized into 
its active form, the seco-steroid hormone 1α,25-dihydroxyvitamin D3 (1,25(OH)2D), also 
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known as calcitriol, it activates VDR which is expressed in different cellular tissues such 
as skin and hair. Resistance of VDR is related to rickets, a hereditary disease that is caused 
by a receptor mutation that leads to hypocalcemia, osteomalacia and alopecia. However, 
treatments for rickets cannot only suppress alopecia. This indicates that VDR is required 
in postnatal hair growth and maintenance as it is expressed in two fundamental 
communicable regions for the hair cycle regulation, namely dermal papillae and 
keratinocytes cells [31].   
In vitro studies have shown that VDR is found in high concentrations during late 
anagen and catagen phases which are characterized by a decrease in cell division and an 
enhancement in differentiation. It is suggested that the lack of VDR expression might be 
the cause for observed alopecia. In addition, studies have been demonstrating that VDR is 
also somehow correlated with Hairless (Hr) gene, retinoid X receptor (RXR) and Wnt 
signaling [47]. For instance, it is thought that VDR regulates Hr expression due to high 
levels of Hr detected in VDR knockout mice, but not in the wild-type mice [47]. The 
heterodimerization formed by VDR and RXR is essential for maintenance of the hair cycle 
as RXR knockout mice exhibit similar alopecia patterns compared with VDR knockout. 
Therefore, the involvement of VDR with these protein receptors may be a reasonable 
explanation for alopecia induced by deregulation of VDR as many other signaling 
pathways are involved in CIA [47]. Topical application of VDR is a proposed treatment to 
reduce the activity of chemotherapy agents which are ABCB1 substrates in the HF [4]. 
(Table 3.1) 
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VDR belongs to the NR superfamily and its activation is mediated by the binding 
of 1,25-(OH)2D. The VDR is comprised of 13 α-helices and 3 β-sheets, which residues of 
H3 and H5 are involved in the ligand binding domain activation by 1,25-(OH)2D. In 
particular, residues Arg274 (H5), His305 (loop H6-H7) and His397 (H12) promote the 
receptor ligand affinity and activity [48]. A derivative of calcitriol, the antagonist (23S)-
25-dehydro-1α-hydroxyvitamin D3-26,23-lactone (TEI-9647) is found to inactive VDR by 
interacting with residues His397, Tyr143, Ser237, Arg274 and Ser278. Among those 
interactions, TEI-9647 binds to residue His397 and changes the conformation of H12 in a 
way that allows a covalent bond formation among residues Cys403 or Cys410. The 
presence of either cysteine residues at the C-terminal of VDR confers antagonism of the 
receptor [49]. Therefore, the binding of TEI-9647 to VDR requires interaction with residue 
His397 to initiate antagonism of the receptor, whereas the binding of calcitriol requires 
interaction mainly with residue His305 for receptor activation [48, 49]. 
The structure of the antagonist TEI-9647 only differs in the C23 position of 
calcitriol, whereas the 25-OH is replaced by a bulky lactone ring that prevents the closure 
of helix 12 of the VDR, a remarkable feature for receptor activation. Other mechanism 
proposed is that the methylene group attached at the C25 group of lactone ring can react 
with either Cys403 or Cys410 residues, thus inactivating VDR [49]. (Figure 3.3) 
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Figure 3.3: Chemical structures of endogenous substrate of vitamin D receptor A) 1α,25-
(OH)D3 and B) Antagonist TEF-9647.  
 
3.1.4.1.5 Fibroblast-Growth Factor 
Fibroblast-growth factor (FGF) is a ligand protein that interacts with FGF receptor (FGFR). 
There are at least 22 different FGFs that are divided into subfamilies that bind to four types 
of FGFRs (1-4) [50]. Beenken et al. [50] and Ornitz et al. [51] have thoroughly illustrated 
the classification, biology, pathophysiology, therapy and signaling cascade of FGF-FGFRs 
complex. They reviewed that the activation of FGF-FGFR complex protein is mainly 
mediated by the recruitment and binding of heparin sulphate glycosaminoglycan that 
strengths protein-protein interaction. After coupling, the ligand-receptor interact with 
another ligand-receptor to form a 2:2 FGF-FGFR-heparin complex dimer required for 
downstream signal transduction responses [50, 51]. Once the FGF-FGFR-heparin complex 
is formed, the activation of the receptor occurs upon ATP binding to and phosphorylation 
of the tyrosine kinase domain, a region that contains different residues from those 
participating in the heparin binding [52].  
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FGF5 has been strongly related with a negative controlling of the hair length. Its 
activation induces the HF to undergo an earlier catagen phase, thus diminishing the length 
of the hair. Studies have been shown that FGF5 knockout in mice increases the hair length 
[53, 54]. Overexpression of FGF5 in the dermal papilla cells of cashmere goats leads to an 
increase in BMP4 expression and to a decrease in noggin levels. This demonstrates the 
negative effect on the HF induced by FGF5 as BMP4 itself also induces early catagen and 
apoptosis in the HF [32]. Moreover, FGF7 also known as KGF (keratinocyte growth 
factor), is thought to protect the HF from CIA through regulation/stimulation of BCL2 and 
PI3K. FGF7 inhibits free radicals to induce apoptosis, but the exactly mechanism is not yet 
known [3, 4, 33]. (Table 3.1) 
3.1.4.1.6 Epidermal Growth Factor 
Epidermal growth factor (EGF) is involved in cell differentiation and proliferation. The 
signaling of epidermal growth factor receptor (EGFR) is negatively correlated with the hair 
cycle maintenance. Activation of EGFR is likely to induce early catagen phase transition 
within the HF as EGFR inhibition by gefitinib reduced alopecia in breast cancer patients 
[36]. Bichsel et al. have tested both cyclophosphamide-chemotherapy in EGFR knockout 
mice and in EGFR inhibitor-treatment and showed that alopecia was not developed in any 
model [36]. The mechanism behind EGFR effect is that if the receptor is knockdown, less 
cell proliferation in the hair follicle is observed, thus preventing or diminishing alopecia 
development [36]. (Table 3.1) 
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3.1.4.2 Cellular Control Pathways 
Cancer is caused by many dysregulated cell functions such as upregulated mitosis and 
impaired apoptosis. For instance, after uncontrolled cell proliferation, cells accumulate in 
the cellular tissue due to an imbalance of pro-apoptotic and anti-apoptotic factors. The p53 
transcriptional factor is known as a fundamental factor causing of alopecia induced by 
chemotherapy as it is related to cellular stress level and apoptosis [3, 4, 7, 18, 19].  
3.1.4.2.1 Pro- and Anti-Apoptotic Proteins 
During cancer treatment, p53 is normally found in high concentrations to promote 
upregulation of pro-apoptotic proteins First-Apoptosis Signal Receptor (FAS) and B-cell 
lymphoma-2-like protein 4 (BAX), and downregulation of anti-apoptotic protein B-cell 
lymphoma-2 (BCL-2). In the HF, increased levels of p53 in chemotherapy-treated mice are 
specifically seen in the outer and inner root sheaths. The high levels of p53 induces 
increased levels of FAS and BAX, and decreased levels of BCL-2, that potentially leads to 
the death of HF and alopecia during chemotherapy [3, 4, 17-19, 37]. (Table 3.1) 
Sharov et al. have demonstrated that mice receiving cyclophosphamide but treated 
with anti-FAS ligand-neutralizing antibody did not result in alopecia [37]. The endogenous 
substrate of FAS, FAS ligand (FASL), exists in a trimeric form. FAS is a transmembrane 
protein type I and FASL is a transmembrane protein type II that belongs to the tumor 
necrosis factor superfamily (TNFSF). The interaction among ligand and receptor recruits 
a FAS-associated protein with death domain (FADD) that in turn activates caspase-8 to 
trigger apoptosis. Residues at the C-terminal loop of FASL seem to play a crucial role in 
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the binding of FAS [55]. Schneider et al. have shown that for one molecule of FAS, two 
of FASL are required for protein-protein interaction and activation of FAS signaling [56].  
3.1.4.2.2 p53 Factor and Murine Double Minute 2 Homolog  
p53 transcriptional factor is mainly regulated by murine double minute 2 homolog 
(MDM2), an E3 ubiquitin ligase protein that forms a complex with p53 [57]. Under normal 
cell stress conditions, MDM2-p53 complex is broken causing release of p53 to initiate 
apoptosis. In cancer cells, however, there is an overexpression of MDM2 that leads to 
inactivation of p53 function, thus impairing the normal apoptotic mechanism regulated by 
p53 [17, 58]. The activation of p53 pathway is controlled by an auto-regulatory feedback 
loop of MDM2 which inhibition of MDM2 leads to disruption of the complex and 
activation of p53. Thus, an inhibitor of MDM2 could promote apoptosis-induced by p53 
[38, 59]. (Table 3.1) 
Kussie et al. have identified the interaction among p53 and MDM2 in human 
species [57]. The transcriptional factor p53 is a small helical peptide of 15 residues that 
interacts with the hydrophobic cleft of MDM2 [57]. MDM2 is a protein of 85 amino acids 
length which structure is divided in two similar portions consisted of repeated β strands 
and α helices. The transcriptional factor p53 interacts with both α2 helix and β-sheet of 
MDM2 through VDW contacts and H-bonds [57].  
The findings above has aroused special attention in the oncology field for the 
development of small molecules that could inhibit MDM2 hence activate p53 function. A 
virtual screening of cis-imidazole analogs called nutlins, have shown to have the same type 
of interactions seen among p53 and MDM2. More specifically, nutlins can mimic the 
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binding interactions of Phe19, Trp23 and Leu26, known residues of p53 that are involved 
in the binding of MDM2. Thus these small molecules can potentially inhibit MDM2 that 
in turn leads to the activation of p53 hence apoptosis [38]. (Table 3.1) 
A number of hydrophobic residues are involved in the binding of nutlin-2 within 
the binding pocket of MDM2. In particular, the main chain of residue Gln72 of MDM2 
makes one H-bond with the HBD group of hydroxyl of nutlin-2 [38]. Essentially, the 
bromo-substituent phenyl rings and the ethyl moiety of the ligand sits where Trp23, Leu26 
and Phe19 residues of p53 are located. Nutlin-2 has a chemical formula of C31H34Br2N4O4 
with a MW of 686.45 g/mol [38, 60]. (Figure 3.4) 
 
Figure 3.4: Chemical structure of nutlin-2 inhibitor of MDM2-p53 complex. 
 
3.1.4.2.3 Cyclin-Dependent Kinase 2 
Cyclin-dependent kinase 2 (CDK2) is a p53 target and is also involved in DNA-damage 
through cell-cycle arrest. This protein is likely to be activated during CIA by promoting 
cell cycle arrest and apoptosis. Inhibitors of CDK2 can decrease the damage within the HF 
caused by the chemotherapeutic agent, thus preventing apoptosis [1]. A natural inhibitor of 
CDK2, p21, has been associated with possible targets during CIA as it is expressed in the 
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keratinocytes, more specifically in the post-mitotic phase of the HF [4, 37]. Thus, inhibitors 
of CDK2 have been suggested to prevent CIA, however, a combination of therapy should 
be indicated in this case to not compromise the effectiveness of treatment as it could stop 
cell death [17, 37, 61]. (Table 3.1) 
3.1.4.2.4 ABC Transporters 
ABC transporters also known as ATP-binding cassette transporters use the energy released 
from ATP hydrolysis to remove a variety of substrates such as ions, amino acids, 
metabolites, lipids and drugs out of the cell. These transporters are involved in the removal 
of cytotoxic elements from the cell, therefore protecting the cell from the accumulation of 
anticancer agents, for instance. Haslam et al. have tested which chemotherapy induced 
agents are substrates of ABC family transporters [4]. They found that vindesine and 
vinorelbine, both vinca alkaloids drugs as VLB, are substrates of ABCB1 and ABCC1 
transporters. VLB is well known to behave both as a substrate and inhibitor of subtype 
ABCB1, also known as P-glycoprotein (P-gp) or MDMR1 [4, 62].   
ABC transporters might also be involved in protection of epithelial HF stem cells. 
ABC family transporters are located in the outer root sheath of the lower isthmus, which, 
specifically, subtype ABCC1 is more expressed in the HF than the others. ABCC1 seems 
to be highly expressed in the bulge and non-bulge HF at the outer root sheath of the HF for 
protection of the keratinocytes. Studies have suggested that by increasing the expression 
of ABC transporters in the epithelial hair follicle stem cell, the prevalence of CIA is 
reduced, thereby prevent damage in the HF [4]. (Table 3.1) 
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3.1.4.3 Hair Follicle Pathways  
3.1.4.3.1 Notch Signaling 
Notch are transmembrane proteins that are expressed throughout the HF, but especially in 
the proliferating matrix cells, hair bulb and outer root sheath. Notch has been strongly 
related to embryogenesis process as well as postnatal life of the HF. The expression of this 
protein and its ligands occur differently throughout the hair cycle [28]. A study performed 
in transgenic newborn mice has shown that overexpression of notch is involved in the 
development of abnormalities of HF and alopecia [29], thus demonstrating that notch 
expression is not required for early development of HF during embryogenesis. On the other 
hand, research have shown that knockdown mice of either notch or its ligands in postnatal 
mice leads to hair shortening and alopecia, hence suggesting the requirement of Notch 
signaling during HF development [28]. (Table 3.1) 
Notch receptor contains two O-glycan in both serine residues 458 and 496; one O-
flucose at Thr466; and one hexose at Ser435. In the EGF12 domain of notch receptor, 
residues Leu468, Asp469, Ile477 and Thr466-O-fucose interact with either Jagged or DLL, 
natural protein ligands of Notch. Residues Glu450 and Asp452 from the EGF11 also seem 
to be involved in the binding ligand-receptor. Among the glycosylated-residues, only 
Thr466-O-fucose directly interacts with the ligand whereas Ser435-O-glycan might 
indirectly aid in proteolytic cleavage of Notch, required for activation of the downstream 
signaling [63]. (Figure 3.1) 
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3.1.4.3.2 Bone Morphogenetic Protein and Noggin Signaling 
Bone morphogenetic protein (BMP) is related with a variety of development signaling 
during embryonic process. BMP is secreted in many different types of cells such as bone, 
hair, skin and etc. The regulation of BMP occurs through inactivation by Noggin protein, 
an antagonist of BMP. This antagonism allows cell proliferation and growth in normal cell 
conditions. Thus, BMP by itself works as a negative controller of HF as its activation or 
inhibition of Noggin that can lead to minimization of HF and then alopecia. The only 
known BMP receptor in the HF is BMPRIA, which is expressed in the inner root sheath 
and hair shaft [11]. (Figure 3.1 and Table 3.1) 
BMP residues involved in Noggin binding are Trp52, Trp55, Phe75, Val87, 
Lys126, Tyr128, Met131, whereas noggin residues contacting BMP are Pro35, Asp39, 
Leu46, Glu48, Val186, Arg206, Ile218 and Cys232. Interestingly, noncovalent interactions 
with proline, leucine and isoleucine are the most important ones [64].  
3.1.4.3.3 Sonic Hedgehog Signaling 
Sonic Hedgehog (Shh) signaling is involved in embryonic and adult HF development and 
cycling. Xie et al. have demonstrated that feather proliferation is reduced, and that Shh 
transcription is downregulated during treatment with cyclophosphamide in chicken [26]. 
The authors have tested other chemotherapeutic drugs such as taxol and 5-fluoracil. 
According to Xie et al., taxol, an antimicrotubule just as VLB, seems to downregulate Shh 
expression in the chicken HF. Surprisingly, the same effects were demonstrated in murine 
HF, thus indicating that downregulation of Shh expression is also present in mammalian 
tissue as well [26]. (Table 3.1) 
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Both Shh and Wnt signaling work as crosstalk pathways, which activation of Wnt 
pathway can also regulate the Shh downstream signaling. [25]. The activation of Shh 
signaling is mediated by Shh ligand binding to PTCH1 that induces the release of 
Smoothened receptor (SMO) to stimulate cell responses. SMO protein also belongs to the 
Frizzled (FZD) classification of receptors. Thus, SMO activates the downstream signaling 
of Shh pathway by recruiting GLI and initiating cell responses within the HF. (Figure 3.1)  
An extracellular domain (ECD) comprising a cysteine-rich domain (CRD), and 
ECD linker domain, a seven transmembrane helical domain (7TM) and a carboxy-terminal 
domain located intracellularly form the FZD structure of receptors. SMO protein also 
resemble the GCPRs due to their location at the cellular membrane, however, it only shares 
10% of sequence identity with GCPRs [27].  
Activation of hedgehog pathway is highly involved in cell proliferation and thus 
used as a cancer target, whereas inhibitors of SMO have significantly contributed to tumor 
suppression [65]. Despite the unknown identity of endogenous substrates that regulate 
SMO activity, a number of exogenous ligands have been developed. Among those, 
cyclopamine was the first inhibitor of Shh signaling discovered by directly modulating 
SMO through inhibition of its downstream signaling effect. In addition, the human crystal 
structures comprising the SMO-inhibitor complexes such as cyclopamine (4O9R) [66], 
LY2940680 (4JKV) [27], anta XV (4QIM) and SANT1 (4N4W) [65] are available. The 
exogenous agonist of SMO, SAG 1.5, have been also crystallized (4QIN) [65]. These 
designed compounds all bind to the narrow binding pocket of SMO which is characterized 
by the seven-transmembrane domain, ECD and ECLs of SMO [65]. 
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In the SMO-cyclopamine complex (4O9R) [66], the structure of SMO is shown as 
a monomer whereas in the SMO-LY2940680 structure (4JKV) [27], SMO is represented 
as a dimer. The binding pocket of SMO receptor is narrow, long, and located at the ECD, 
extracellular loops 2 and 3 whereas helices I, II, V and VII interact with the antagonists. 
Residues Arg400, Lys395, Asn219, His470, Tyr394, Glu518, Asp473 are involved in the 
binding of antagonists cyclopamine, LY2940680, anta XV and SANT1, whereas residues 
Asp473 and Asn219 are mainly involved in binding with the agonist SAG1.5 of SMO [27, 
65, 66]. Although both agonist and antagonist bind to the same binding pocket of SMO and 
share similar residues, their binding strength vary depending on the residue [27].  
Cyclopamine is a natural steroidal alkaloid derived from Veratrum californicum 
gene of plants that was initially discovered as a teratogen chemical due to an abnormal eye 
formation in newborn lambs [67]. Cyclopamine was later related to embryonic and post-
natal developmental phases as it inhibits Shh signaling by directly binding to the ECD of 
SMO. Residue Glu518 of SMO is involved in a H-bond with the inhibitor [66, 67]. As 
cyclopamine, anta XV is also a small molecule inhibitor of SMO with a higher MW than 
cyclopamine (439.6 g/mol compared to 411.6 g/mol). The agonist SAG1.5 has a MW of 
564 g/mol due to two fluorine atoms attached at the benzothiophene group. (Figure 3.5)  
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Figure 3.5: Chemical structures of SAG1.5, cyclopamine and anta XV. 
 
3.1.4.3.4 Canonical Wingless-Related Integration Site and β-Catenin 
Wingless-related integration site, also known as Wnt signaling, is divided into three 
pathways known as Canonical Wnt/β-catenin, Noncaninocal Wnt/β-catenin, and 
Wnt/Calcium. The canonical Wnt/β-catenin pathway is the one involved in HF 
proliferation and cell maintenance, which Wnt ligand is present in different phases of the 
HF cycle [7]. Wnt/β-catenin signaling induces cell response when Wnt binds to the Frizzled 
(FZD) receptor along with the co-receptor Low Density Lipoprotein Receptor Related 
(LRP) [68], thus forming a complex FZD-Wnt-LRP. The binding of Wnt to FZD and LRP 
causes phosphorylation of the cytoplasmic tail of LRP that sends signals to Dishevelled 
(Dsh) protein. This process inhibits the scaffold complex and leads to the accumulation of 
β-catenin. In the cytoplasm, the stabilized and non-phosphorylated form of β-catenin act 
as a transcriptional factor upon interaction of TCF/LEF with DNA-binding proteins. This 
causes initiation of a signaling cascade required for the HF development, including cell 
proliferation, migration and differentiation. This complex signaling is inhibited by a natural 
endogenous antagonist of Wnt, Dickkop (DKK) protein [69]. In a normal hair cycle, 
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Wnt/β-catenin signaling is active during anagen phase and it is required for HF 
maintenance throughout life [23, 68-70]. (Figure 3.1) 
Wnt ligands are lipid-modified proteins that bind to the cysteine-rich domain 
(CRD) of FZD [68]. The CRD-FZD domain has been shown to be sufficient for signaling 
and binding of Wnt [69]. LRP5/6 has four β-propellers that are structures arranged 
toroidally followed by an epidermal-growth factor like, which the third and fourth domains 
(E3E4) are involved in binding [69]. There are currently 19 subtypes of Wnt, 10 FZD and 
2 LRP in the mammalian tissue, hence different complexes can be formed. Although it is 
still not clear if all of them have biological relevance, the most known subtypes are Wnt3a, 
FZD8 and LRP6. The complete downstream mechanism by which Wnt pathway is 
activated/inhibited remains unknown, however, it is established that Wnt binds to both 
FZD and LRP for pathway activation and this interaction is prevented by DKK1 [69]. 
According to Bourhis et al., the binding of DKK1 disrupts Wnt3a-LRP6 but not Wnt3a-
FZD8 complexes, however this disruption is enough for prevention of the signaling. This 
also demonstrates the higher affinity of DKK1 for LRP6 than for FZD [69]. Moreover, it 
is suggested that one molecule of DKK1 can recognizes both E1E2 and E3E4 sites at LRP6 
and inhibits a variety of Wnt ligands as they bind specifically to either E1E2 or E3E4, 
depending upon their subtype [69, 70].  
 This chapter focuses on the effects of VLB and its metabolites docked with protein 
receptors that are involved with alopecia induced by chemotherapy. Due to limited time, 
throughout the project program, this study covers only four receptors for molecular docking 
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with VLB and its metabolites, which are the mouse double minute 2 homolog (MDMD2), 
vitamin D receptor (VDR), androgen receptor (AR) and smoothened receptor (SMO).  
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3.2 Materials and Method 
The crystal structures retrieved from the Protein Data Bank (PDB) were minimized with 
AMBER7 FF99 force field using SYBYL®-X 2.1.1 simulation package. Water molecules 
in the PDB files were removed, polar hydrogens were added and the side chains of residues 
were completed when they were unsolved in the crystal structures. All of the protein 
structures used in this study contain their ligand crystallized with the receptor, such as 
testosterone with AR (2AM9) [41], nutlin-2 with MDM2 (1RV1) [38], calcitriol with VDR 
(1DB1) [48], and anta XV with SMO (4QIM) [65]. For preparation of the ligands regarding 
VLB and its metabolites, please see the Materials and Method section of Chapter 2. The 
docking results with the lowest binding energy of each natural ligand or inhibitor were 
considered for further analysis of their binding profile.  
 AR: The binding site of the endogenous substrate of AR is surrounded by eleven 
α-helices and two β-sheets (UniProtKB P10275) [41]. The structure of AR is comprised of 
266 amino acids which are divided into α1 (residues 671-681), a flexible linker (682-695), 
α2 (696-721), α3 (724-728), α4 (729-758), an antiparallel β-sheet (762-770), α5 (771-778), 
α6 (780-797), α7 (800-813), α8 (823-844), α9 (848-884), α10 (892-902) and α11 (902-
908). A spherical region with a radius of 20 Å around the ligand testosterone was used as 
the binding site for molecular docking of VLB, its metabolites and the substrate into AR.  
VDR: The PDB entry 1DB1 (UniProtKB P11473) [48] comprises the crystalized 
structure of the agonist and VDR, which is also used for molecular docking of the 
antagonist, TEI-9647, into the receptor. The VDR is formed by 14 α-helices and 3 β-sheets, 
defined as α1 (residues 125-143), α2 (149-153), α3 (216-224), α4 (226-247), α5 (250-254), 
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α6 (255-275), α7 (290-292), α8 (296-302), α9 (306-323), α10 (326-339), α11 (348-371), 
α12 (378-406), α13 (410-414) and α14 (415-423). A spherical region with a radius of  
10 Å around the ligand was selected for the binding target of VLB, its metabolites, calcitriol 
and TEF-9647 into VDR. 
MDM2: Four α-helices defined as α1 (residues 31-40), α2 (50-64), α3 (80-87), α4 
(95-105) comprises receptor MDM2 (UniProtKB Q00987) [38]. A spherical region with a 
radius of 15 Å surrounding residue Gly58 was selected as the binding target site for the 
docking of VLB, its library and nutlin-2 into MDM2 receptor. 
SMO: The binding site of SMO receptor is surrounded by the seven transmembrane 
domain, ECD and ECL 2 and 3. The crystal structure 4QIM (UniProtKB Q99835) contains 
468 residues and is comprised of 20 α-helices [65]. Helices 10 and 11 formed by residues 
396-404 and 405-1020, respectively, are mainly involved with the binding of antagonists 
and agonists of SMO. Therefore, a spherical region with a radius of 20 Å surrounding the 
anta XV was defined as the target site for the docking of antagonists, VLB and its 
metabolites.  
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3.3 Results and Discussion 
3.3.1 Androgen Receptor 
VLB, its metabolites and testosterone were docked into the binding pocket of androgen 
receptor as described in the Materials and Method section of Chapter 3. VLB and most of 
its metabolites did not obtain any docking solution in the AR. (Table 3.2) 
3.3.1.1 Testosterone Binding to AR 
Testosterone has a binding energy of -20.45 kJ/mol in the binding pocket of AR. 
Hydrophobic interactions are mainly seen with residues Met895, Gln711, Met745, Gly708 
and Phe764. The ketone group at C3 shares its electrons to the guanidinium group of 
Arg752 within a distance of 1.9 Å, and the hydroxyl group makes two H-bonds with 
Asn705 and Thr877 within a distance of 3.0 Å and 2.1 Å, respectively. (Figure 3.6B) 
3.3.1.2 Vinblastine and its Metabolites Binding to AR 
The majority of metabolites of VLB, including the anticancer drug do not interact with AR. 
Metabolite 22 is the only one which has a binding affinity (-19.79 kJ/mol) near the binding 
energy of the natural substrate (-20.45 kJ/mol) for AR. Metabolite 22 interacts with two 
residues involved the binding pocket of testosterone, Arg752 and Gln711. The 
azacyclononane ring and the indole ring of metabolite 22 interact through hydrophobic 
interactions with residues Arg752 and Gln711, respectively. In addition, metabolite 22 
makes H-bonds with the main chains of Gly683 and Val685, and with the side chain of 
Glu681. Hydrophobic interactions with residues Trp751 and His714 are also observed. 
This shows that metabolite 22 may be involved on the onset of alopecia through binding to 
AR. (Table 3.2 and Figure 3.6C) 
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Table 3.2: Binding energies of VLB, its metabolites and testosterone docked into androgen 
receptor. The energy value of the metabolite with the lowest binding energy is shown in 
bold. 
Androgen Receptor ΔGbinding (kJ/mol) 
Testosterone -20.45 
VLB NB 
MTB1 NB 
MTB2 NB 
MTB3 NB 
MTB4 NB 
MTB5 NB 
MTB6 NB 
MTB7 NB 
MTB8 NB 
MTB9 NB 
MTB10 NB 
MTB11 NB 
MTB12 NB 
MTB13 NB 
MTB14 NB 
MTB15 NB 
MTB16 NB 
MTB17 NB 
MTB18 NB 
MTB19 6.44 
MTB20 6.79 
MTB21 -1.12 
MTB22 -19.78 
MTB23 -12.78 
MTB24 NB 
MTB25 NB 
MTB26 -8.00 
MTB27 -5.40 
MTB28 NB 
MTB29 -1.08 
MTB30 -3.35 
MTB31 -6.12 
MTB32 -3.78 
MTB33 9.03 
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MTB34 -17.83 
MTB35 -17.58 
NB: non substrate 
 
  
Figure 3.6: A) Pose view of testosterone and metabolites of VLB docked into the binding 
pocket of androgen receptor. Binding interactions of B) Testosterone, and C) Metabolite 
22. Hydrogen bonds are shown in dashed lines. 
 
3.3.2 Vitamin D Receptor 
VLB, its metabolites, calcitriol and the antagonist TEI-9647 were docked into the binding 
pocket of vitamin D receptor as described in the Materials and Method section of Chapter 
3. Due to the narrow size of the binding pocket of VDR, only metabolite 22, metabolite 23 
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and metabolite 34 could bind into the receptor, whereas the lowest binding energy was for 
metabolite 23 (-16.70 kJ/mol). (Table 3.3) 
3.3.2.1 Calcitriol Binding to VDR 
The binding energy calculated for calcitriol docked into the vitamin D receptor was  
-17.81 kJ/mol. Calcitriol makes an H-bond within the binding site of VDR with residue 
His305, which confers specificity and activation of the receptor. The 25-OH group acts as 
both hydrogen bond acceptor and donor with residues His305 and His397, within a distance 
of 1.9 Å and 1.7 Å, respectively. Moreover, the hydroxyl groups attached to the 
cyclohexane make H-bonds with Arg274, Ser237 and Ser278. Residues Val234, Val300, 
Trp286 and Ile268 participate in hydrophobic interactions with the agonist of VDR. (Table 
3.3 and Figure 3.7B) 
3.3.2.2 TEI-9647 Binding to VDR 
The inactivation of VDR is mediated by an interaction of the inhibitor with residue His397 
that in turn stabilizes H12 by promoting a disulfide bond among residues Cys403 and 
Cys410 [49]. The antagonist of VDR, TEF-9647, has binding energy of -10.42 kJ/mol and 
binds to His397 within a distance of 2.0 Å. The docking results of both agonist and 
antagonist of VDR, demonstrate His397 interacts with calcitriol as an HBA group, while 
with TEI-9647 it interacts as HBD group. The hydroxyl group is placed close to residue 
Cys288, making an H-bond with the thiol side chain. Moreover, the antagonist also makes 
hydrophobic contacts with same residues involved with the agonist. (Figure 3.7C) 
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Table 3.3: Binding energies of VLB, its metabolites, calcitriol and TEI-9647 docked into 
vitamin D receptor. The energy value of the metabolite with the lowest binding energy is 
shown in bold. 
Vitamin D Receptor ΔGbinding (kJ/mol) 
Calcitriol -17.81 
TEI-9647 -10.42 
VLB NB 
MTB1 NB 
MTB2 NB 
MTB3 NB 
MTB4 NB 
MTB5 NB 
MTB6 NB 
MTB7 NB 
MTB8 NB 
MTB9 NB 
MTB10 NB 
MTB11 NB 
MTB12 NB 
MTB13 NB 
MTB14 NB 
MTB15 NB 
MTB16 NB 
MTB17 NB 
MTB18 NB 
MTB19 NB 
MTB20 NB 
MTB21 NB 
MTB22 -12.06 
MTB23 -16.70 
MTB24 NB 
MTB25 NB 
MTB26 NB 
MTB27 NB 
MTB28 NB 
MTB29 NB 
MTB30 NB 
MTB31 NB 
MTB32 NB 
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MTB33 NB 
MTB34 4.05 
MTB35 NB 
           NB: non substrate  
 
3.3.2.3 Vinblastine and its Metabolites Binding to VDR 
The majority of the metabolites of VLB including VLB do not bind to VDR. Metabolite 
23 has a binding affinity calculated as of -16.70 kJ/mol. It interacts with residues His397 
and His305. The HBA group of hydroxyl moiety of metabolite 23 makes an H-bond with 
His397 within a distance of 1.9 Å, 0.1 Å closer than the antagonist and agonist of VDR 
(2.0 Å). On the other hand, the HBD group of hydroxyl makes an H-bond with His305 
within a distance of 2.0 Å. The docking results show that both histidine residues bind to 
the antagonist and to metabolite 23 in a similar fashion, whereas position 397 act as HBD, 
and position 305 as a HBA group. In addition, hydrophobic interactions are seen with 
Val300, Ile268, Ile271, Ser237, Trp286 and Val234. Thus, due to similar binding profiles 
of metabolite 23 and the antagonist TEI-9647 with residue His397, it is suggested that 
metabolite 23 inhibits VDR may induce the onset of alopecia during chemotherapy with 
VLB. (Figure 3.7D) 
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Figure 3.7: A) Overview of interactions into the binding pocket of vitamin D receptor. 
Binding interactions of B) Calcitriol, C) TEI-9647, and D) Metabolites 23. Hydrogen bonds 
are shown in dashed lines. 
 
3.3.3 Murine Double Minute 2 Homolog Receptor 
VLB, its metabolites and nutlin-2 were docked into MDM2 receptor as described in the 
Materials and Method section of Chapter 3. (Table 3.4) 
3.3.3.1 Nutlin-2 Binding to MDM2 
Nutlin-2 has a calculated binding energy of -10.66 kJ/mol in the binding site of MDM2, 
whereas it makes H-bonds with residues His96 and Val93. The hydroxyl group binds to 
the side chain of His96 (1.7 Å) and to the main chain of Val93 (2.1 Å), respectively. The 
protonated nitrogen also binds to residue Val93. The bromo-substituent groups are 
involved in hydrophobic interactions mainly with residues Gly58, Leu57 and Leu54 which 
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also bind to p53 transcription factor [38]. Isoleucine residues at positions 61 and 99 also 
interact with the ligand into MDM2 receptor.  (Table 3.4 and Figure 3.8B) 
3.3.3.2 Vinblastine Binding to MDM2 
Vinblastine has a binding energy of 1.02 kJ/mol for MDM2. Although it interacts with 
residues involved with the binding of Nutlin-2 (i.e. Leu54 and His96), its binding is energy 
consuming and less likely to take place. (Figure 3.8C) 
3.3.3.2 Metabolites Binding to MDM2 
Metabolite 35 has a calculated binding energy as of -18.71 kJ/mol when docked into the 
binding site of MDM2. Hydrophobic interactions are observed with Leu54, Leu57, Gly58, 
Ile61, Met62, Val93 and Ile99, which are seen in the binding of p53 [58] indicating that 
metabolite 35 interacts with the same residues as of p53. The main chain of Leu54 
participates in an H-bond with the protonated nitrogen of metabolite 35 within a distance 
of 1.8 Å. The same type of interactions are observed with metabolite 34, with a binding 
energy of -17.59 kJ/mol and an H-bond with residue Leu54 within a distance of 1.7 Å. 
Therefore, it is expected that metabolite 35 contributes to the onset of alopecia through 
inhibition of the MDM2-p53 complex. (Table 3.4 and Figure 3.8D) 
 All metabolites of VLB which interact with the binding site of MDM2 and have a 
binding energy lower than -10.66 kJ/mol (Nutlin-2) are potential alopecia inducers during 
chemotherapy with VLB. (Table 3.4)  
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Table 3.4: Binding energies of VLB, its metabolites and nutlin-2 docked into MDM2 
receptor. The energy value of the metabolite with the lowest binding energy is shown in 
bold. 
MDM2 ΔGbinding (kJ/mol) 
Nutlin-2 -10.66 
VLB 1.02 
MTB1 -2.43 
MTB2 3.43 
MTB3 4.55 
MTB4 -1.75 
MTB5 0.57 
MTB6 1.90 
MTB7 3.76 
MTB8 2.97 
MTB9 -0.67 
MTB10 3.75 
MTB11 -1.48 
MTB12 -1.63 
MTB13 -10.35 
MTB14 0.00 
MTB15 -0.76 
MTB16 -10.58 
MTB17 -4.42 
MTB18 -9.49 
MTB19 -7.16 
MTB20 0.56 
MTB21 -9.70 
MTB22 -13.85 
MTB23 -11.83 
MTB24 -9.50 
MTB25 -9.70 
MTB26 -10.42 
MTB27 -8.57 
MTB28 -1.95 
MTB29 -7.18 
MTB30 -11.10 
MTB31 -11.37 
MTB32 -6.09 
MTB33 -11.72 
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MTB34 -17.59 
MTB35 -18.71 
             NB: non substrate 
 
Figure 3.8: Interactions with MDM2 receptor. A) p53; B) Nutlin-2; C) Vinblastine, and 
D) Metabolite 35. Hydrogen bonds are shown in dashed lines. 
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3.3.4 Smoothened Receptor 
VLB, its metabolites and the antagonist anta XV were docked into the binding site of SMO 
receptor as described in the Materials and Method section of Chapter 3. (Table 3.5) 
3.3.4.1 Anta XV Binding to SMO 
The binding energy of anta XV docked into SMO receptor was calculated to be  
-33.79 kJ/mol. The antagonist binds to Arg400, Asn219 and Lys395 through H-bonds and 
with His470, Leu522, Leu221, Ser387 and Asp384 through hydrophobic contacts. The 
propanol group act as a HBA group accepting the hydrogen deficient atom of the side chain 
of Lys395 (1.9 Å), the HBD group of Asn219 makes H-bond with the heteroatom of 
pyridine (2.0 Å), and both heteroatoms of benzylphthalazine interact with the guanidinium 
group of Arg400 (2.1 Å and 2.2 Å). (Table 3.5, Figure 3.9A and 3.9B) 
3.3.4.3 Vinblastine Binding to SMO  
VLB has a binding energy for SMO receptor of 1.98 kJ/mol and it could interact with 
allosteric site between helices α2 and α5. Thus, it is suggested that the anticancer drug does 
not play a role in the function of the receptor. (Figure 3.9C) 
3.3.4.4 Metabolites Binding to SMO 
Metabolite 22 has a binding energy of -16.63 kJ/mol against SMO receptor. Although 
metabolite 22 is located next to α11, which is the main helix involved in the binding of 
SMO ligands, it interacts with only one residue that also participates in the interactions 
with anta XV (Lys395) [65]. (Table 3.5 and Figure 3.9A) 
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Table 3.5: Binding energies of VLB, its metabolites and anta XV docked into SMO 
receptor. The energy value of the metabolite with the lowest binding energy is shown in 
bold. 
SMO-Shh ΔGbinding (kJ/mol) 
Anta XV -33.79 
VLB 1.98 
MTB1 -1.55 
MTB2 -0.56 
MTB3 0.74 
MTB4 -1.37 
MTB5 -3.82 
MTB6 1.50 
MTB7 1.26 
MTB8 4.69 
MTB9 -1.23 
MTB10 -7.04 
MTB11 1.94 
MTB12 -1.54 
MTB13 -3.75 
MTB14 -2.29 
MTB15 -1.44 
MTB16 -1.34 
MTB17 5.39 
MTB18 -8.43 
MTB19 -7.87 
MTB20 -4.37 
MTB21 -6.76 
MTB22 -16.63 
MTB23 -10.62 
MTB24 -5.91 
MTB25 -6.95 
MTB26 -5.60 
MTB27 -6.97 
MTB28 -3.71 
MTB29 -11.83 
MTB30 -8.86 
MTB31 -8.45 
MTB32 -5.68 
MTB33 -5.01 
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MTB34 -15.58 
MTB35 -14.89 
NB: non substrate 
 
Metabolite 22 makes H-bonds with residues Glu481, Glu208 and Asn396, and 
hydrophobic interactions with Lys395 and Tyr397. However, it has ~16 kJ/mol higher 
binding energy, thus it cannot compete with anta XV.  (Table 3.5 and Figure 3.10C)  
 
Figure 3.9: A) Overview of interactions with SMO receptor. B) Anta XV; C) Vinblastine, 
and D) Metabolite 22. Hydrogen bonds are shown in dashed lines. 
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3.4 Conclusion 
A variety of complex signaling pathways are involved in inducing anagen to catagen 
transition in the hair follicle, promoting apoptosis and eventually hair loss during CIA [1]. 
In this research, four receptors were evaluated possible off-targets for binding of VLB and 
its metabolites in connection with alopecia adverse reaction during chemotherapy with 
VLB. The receptors chosen cover the known pathways of CIA, such as hormones related 
that includes androgen and vitamin D receptors, cellular control pathways that include 
MDM2 receptor, and the hair follicle cycle signaling which covers Shh-SMO pathway. 
Therefore, this study provides an overview of the molecular signaling involved in CIA, and 
the VLB effect on the likelihood of its metabolites to induce alopecia through the binding 
to these receptors. (Table 3.1) 
In the VDR, metabolite 23 binds to residues His397 and His305 in a similar way to 
the exogenous antagonist TEI-9647, thus it could inhibit the receptor during chemotherapy. 
The binding energy of metabolite 23 is stronger than of TEI-9647 for the binding site of 
VDR (-16.70 kJ/mol vs. -10.42 kJ/mol). Although metabolite 23 has a higher binding 
energy than the endogenous substrate (-16.70 kJ/mol vs. -17.81 kJ/mol), it binds to the 
receptor and could inhibit VDR.  
Studies have shown an association of low levels of calcitriol and the probability of 
developing cancer due to the anti-proliferative and antioxidants effects of vitamin D 
analogs [71, 72]. Kitchen et al. have analyzed the levels of calcitriol in 241 patients under 
6 months of chemotherapy and found that 200 of those have abnormal levels of vitamin D 
(<75 nmol/L) during cancer treatment, thus suggesting that cancer patients have low levels 
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of vitamin D (<75 nmol/L) during chemotherapy [73]. However, it is not clear whether 
cancer or chemotherapy causes a reduction on the levels of calcitriol, even though both will 
eventually lead to low levels of vitamin D. Therefore, due to the binding affinity of 
metabolite 23 and its antagonism behavior in the VDR as well as the associated low levels 
of vitamin D during chemotherapy and/or cancer, metabolite 23 could contribute to the 
onset of alopecia through inhibition of VDR. (Table 3.3) 
In the MDM2 receptor, metabolite 35 has a binding affinity for the binding pocket 
of p53 into MDM2 and similar binding profile to exogenous inhibitor nutlin-2. Metabolites 
of VLB which occupy the same site as of p53 and nutlin-2 in the binding site of MDM2, 
interact with known residues involving p53, such as Gly58, Leu57 and Leu54 [38]. 
Therefore, the metabolites of VLB may inhibit MDM2 receptor inducing alopecia during 
chemotherapy with VLB. (Table 3.4) 
Although the metabolites of VLB do not display significant binding energies for 
the binding site of AR, metabolite 22 interacts with the same residues involved with the 
natural substrate (Arg752 and Gln711). For instance, metabolite 22 interacts with Arg752 
and Gln711, known residues that participate in the activation of the receptor mediated by 
either testosterone or DHT [41]. As seen with vitamin D, the levels of testosterone also 
seem to be lowered during chemotherapy due to the release of cytokines that in turn 
promotes hypogonadism, or low levels of testosterone [74]. Thus, due to the possible low 
levels of testosterone induced by chemotherapy and similar binding profile as of 
testosterone, metabolite 22 may induce the onset of alopecia through activation of AR. 
(Table 3.2) 
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The molecular docking of the exogenous antagonist of SMO, anta XV, has 
demonstrated that the ligand makes H-bonds with Lys395, Arg400 and Asn219 which are 
residues involved in the inhibition of SMO receptor [65]. Metabolite 22 shares one residue 
(Lys395) with the binding network of the antagonist. Its binding affinity is not significant 
as for anta XV (-16.63 kJ/mol vs. -33.79 kJ/mol). However, anta XV is not a natural 
inhibitor of SMO, and thus metabolite 22 in any respect would compete with the exogenous 
antagonist for the binding of SMO. Instead, it is suggested that metabolite 22 may block 
the passage of unknown natural ligands of SMO due to binding to Lys395, thus impairing 
the normal function of SMO receptor and the downstream Shh signaling within the hair 
follicle. (Table 3.5) 
Therefore, this study has demonstrated the effects of VLB and its metabolites on 
alopecia associated receptors. The metabolites of VLB may induce alopecia through 
different mechanisms that lead to HF apoptosis during chemotherapy with VLB, such as 
inhibition of receptors MDM2, SMO and VDR, and activation of AR. 
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CHAPTER 4 Vinblastine and its Metabolites Binding to Tubulin 
4.1 Introduction 
Microtubules (MTs) are complex structures that constitute part of the cytoskeleton. They 
are structurally formed by 13-16 protofilaments of tubulin which are aligned side-by-side 
with a head-to-tail lay out forming hollow cylindrical microtubules. Highly dynamic in 
nature, MTs denote the mitotic spindle of eukaryotic cells and are strongly involved in 
cellular proliferation [1].  
The cellular division promoted by the MTs have made these structures an attractive 
target for anticancer drug design, more specifically by targeting the tubulin heterodimer. 
The structure of tubulin is comprised of two distinct subunits of proteins known as α- and 
β-tubulin that forms the heterodimer of tubulin. Each of these proteins have approximately 
~50 kDa weight and have a high sequence similarity and identity [2, 3].  
The α- and β-subunit of tubulin are comprised of 451 and 445 residues, 
respectively. These dimers can adopt different conformations depending on their 
GTP/GDP-bound state. The heterodimer αβ-tubulin polymerizes in the presence of GTP in 
the microtubule ends, a process known as the growing phase. On the contrary, the presence 
of GDP can induce depolymerization of the microtubules, known as the shrinking phase. 
These two states are also recognized as assembly and disassembly of the MTs, respectively 
[2, 3].  
VLB targets the MTs by inhibiting the polymerization of the protofilaments 
impairing the mitotic spindle of cells that would divide [4]. Our lab has previously 
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demonstrated the binding interactions of VLB with the αβ-tubulin heterodimer by 
molecular dynamics [1]. In addition, our research group has investigated how carbon 
nanotubes function as a drug delivery option for VLB in order to enhance target specificity 
and decrease ADRs [5]. This chapter looks into whether the metabolites of VLB can also 
display a similar mode of action to that of VLB and elucidate the possibility of chemical 
modifications of VLB structure to reduce production of several metabolites, while 
maintaining its anti-mitotic function, with minimum side effects.  
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4.2 Materials and Method 
The preparation of the ligand library consisting of VLB and its metabolites used for their 
docking into the vinca site of tubulin is described in the Materials and Method section of 
Chapter 2. The crystalized structure of tubulin was retrieved from Protein Data Bank with 
entry code of 4EB6 [6]. Water molecules were removed, side chains with missing residues 
were completed and atom charges were set as appropriate. Protonation states were adjusted 
prior to energy minimization with AMBER7 FF99 force field. The crystal structure used 
in this study (4EB6) is originated from Ovis aries species (sheep). However the amino 
acids sequence is more than 90% similar to the human sequence. The residues known to 
be involved in the binding of VLB share 100% sequence identity with the Homo sapiens 
[4, 6]. 
The α-subunit is folded to 18 α-helices considering in α1 (residues 10-21), α2 (22-
25), α3 (48-51), α4 (72-81), α5 (82-85), α6 (102-108), α7 (109-127), α8 (148-162), α9 
(182-195), α10 (206-211), α11 (223-239), α12 (239-244), α13 (297-301), α14 (324-337), 
α15 (381-386), α16 (387-401), α17 (404-411) and α18 (415-435). The β-subunit is also 
folded to 18 α-helices which are comprised of α1 (residues 10-29), α2 (73-77), α3 (88-90), 
α4 (102-108), α5 (108-128), α6 (147-161), α7 (182-198), α8 (206-211), α9 (224-239), α10 
(251-260), α11 (287-295), α12 (296-301), α13 (306-310), α14 (324-339), α15 (340-343), 
α16 (384-400), α17 (405-410) and α18 (415-437). The structure of tubulin crystalized with 
VLB [6] shows that the drug binds to the interface of β- and α-tubulin. Thus, a spherical 
region with a radius of 10 Å surrounding the reference ligand was selected as the target site 
for docking VLB and its metabolites. 
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4.3 Results and Discussion 
4.3.1 Vinblastine and Metabolites Binding to Tubulin 
Vinblastine and its metabolites were docked into the vinca site of tubulin as described in 
the Materials and Method section of Chapter 4 and Chapter 2. (Table 4.1) 
4.3.1.1 Vinblastine Binding to Tubulin  
The virtual screening of the ligand library docked into tubulin vinca site results in a binding 
energy of -11.23 kJ/mol for VLB. The conformation adopted by VLB at the vinca site of 
tubulin shows that the catharantine portion plays a major role in the binding interactions. 
VLB makes H-bonds with residues Asn329 and Lys336 of α-tubulin along with residues 
Lys176 and Val177 of β-tubulin. All of the residues located at β-tubulin interacting with 
VLB are in agreement with previous research [1, 7, 8]. The catharantine portion of VLB 
which is known to play a major role in the interactions with tubulin [1, 7-9], is also in 
agreement with the findings for the best binding energy of VLB into the vinca site of 
tubulin. (Figure 4.1 and Table 4.2) 
More specifically, the protonated N16ʹ interacts with the carbonyl group of the main 
chain of Lys176 within a distance of 2.3 Å; the hydroxyl group at C4ʹ interacts with the 
main chain of Val177 within a distance of 1.9 Å; the carbonyl of ester at C18ʹ interacts 
with the amide group of Asn329 (2.1 Å), and the carbonyl group at C3 interacts with 
Lys336 within a distance of 2.3 Å. (Figures 4.1, Figure 4.2B and Table 4.3) 
 
153 
 
Table 4.1: Binding energy of VLB and its metabolites docked into the vinca site of tubulin. 
The energy value of the metabolite with the lowest binding energy is shown in bold. 
Drug & Metabolites ΔGBinding (kJ/mol) 
VLB -11.23 
MTB1 -10.05 
MTB2 -9.32 
MTB3 -10.99 
MTB4 -0.45 
MTB5 -9.78 
MTB6 -3.33 
MTB7 -6.43 
MTB8 -12.18 
MTB9 -1.87 
MTB10 -13.39 
MTB11 -14.24 
MTB12 -9.84 
MTB13 -17.94 
MTB14 -9.17 
MTB15 -6.92 
MTB16 -12.93 
MTB17 -0.43 
MTB18 -16.32 
MTB19 -21.90 
MTB20 -5.43 
MTB21 -15.30 
MTB22 -20.12 
MTB23 -18.60 
MTB24 -13.88 
MTB25 -16.68 
MTB26 -10.57 
MTB27 -11.88 
MTB28 -5.27 
MTB29 -16.39 
MTB30 -16.20 
MTB31 -17.13 
MTB32 -15.15 
MTB33 -12.34 
MTB34 -18.58 
MTB35 -16.68 
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Figure 4.1: Binding interactions of VLB docked into the vinca site of tubulin. 
 
Table 4.2: Residues involved in the binding of VLB into the tubulin heterodimer. Residues 
shown underlined bind through H-bonds with the catahrantine portion and in italic with the 
vindoline portion of VLB.  
Subunit Hydrogen Bonds Hydrophobic Interactions 
α-tubulin Asn329, Lys336 Leu248, Ile332 Thr349, Gly350, Phe351, Val353 
β-tubulin Lys176, Val177 Ser178, Asp179, Tyr210, Pro222 
 
4.3.1.2 Metabolites Binding to Tubulin 
VLB and its metabolites were docked into the vinca site of tubulin. Most of the VLB 
metabolites bind to the heterodimer of tubulin and their binding energy vary from  
-21.90 kJ/mol (metabolite 19) to -0.45 kJ/mol (metabolite 4). (Table 4.2) 
Metabolite 19 has the lowest binding energy among the metabolites, calculated as 
of -21.90 kJ/mol, compared to highest binding energy -0.43 kJ/mol of metabolite 17. That 
could be due to the fact that the three aromatic rings of vindoline portion of VLB are opened 
after metabolism and thus gives metabolite 19 more flexibility to find a conformation that 
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fits deep in the binding pocket of tubulin. Although metabolite 19 makes an H-bond with 
Asn329 (α-tubulin) similar to VLB [1], with a shorter distance (1.6 Å vs. 2.1 Å), and with 
a stronger binding energy than VLB (-21.90 kJ/mol vs. -11.23 kJ/mol), the metabolite does 
not bind to all of the residues interacting with VLB. However, metabolite 19 makes  
H-bonds with residues from β-tubulin that are also involved in binding interactions with 
VLB such as Asp179 and Pro222. Moreover, hydrophobic interactions are observed with 
Ser178, Val177, Tyr210 (β-tubulin) and Leu248 (α-tubulin), while all of them also interact 
with VLB. Although metabolite 19 has a high binding energy for the vinca site of tubulin 
and share a few similar residues involved in the VLB binding, it is not likely that it gives 
the same conformational changes on the tubulin structure as its parent drug. Different from 
VLB, metabolite 19 interacts with more residues of β-tubulin than of α-tubulin. Thus the 
structure of tubulin is likely to adopt other induced-fit conformation upon binding of 
metabolite 19. More research is required to evaluate whether metabolite 19 would induce 
the same conformation state of tubulin as VLB to impose depolymerization effect. (Figure 
4.2D) 
Metabolites that have adopted similar conformation to that of VLB in the vinca site 
of tubulin are metabolite 8, metabolite 10 and metabolite 11. These compounds have 
additional moieties in their structure that enhances their binding affinity for tubulin. 
Metabolite 11 has undergone an N-oxidation reaction at N6ʹ during metabolism of VLB. 
Metabolite 10 is hydroxylated at position C20 of VD and metabolite 8 has gone through 
aromatic hydroxylation at C13ʹ of CT. (Figure 1.3 – M10 and M11) 
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Besides adopting similar conformation of VLB at the tubulin heterodimer, 
metabolite 8, metabolite 10 and metabolite 11 have stronger binding energy (-12.18 kJ/mol, 
-13.39 kJ/mol and -14.24 kJ/mol, respectively) than VLB (-11.23 kJ/mol). As expected, 
these metabolites bind to the same residues that interact with the parent drug through H-
bonds (Lys176, Val177, Asn329 and Lys336). However, the strength of these interactions 
and high binding energy are due to the close proximity of atoms involved in H-bonds. 
(Table 4.3)   
Table 4.3: Distances among heteroatoms of the vinca site of tubulin and heteroatoms of 
VLB, metabolites 8, 10 and 11 involved in hydrogen bonds. 
Subunit 
H-bonds 
Interactions 
Distance among HBD and HBA atoms (Å) 
VLB MTB8 MTB10 MTB11 
CT 
N16ʹ + Lys176 2.3 2.2 2.4 2.3 
OH + Val177 1.9 2.0 2.0 1.7 
VD 
Ester C4 + Asn329 2.1 2.0 2.1 1.9 
Ester C3 + Lys336 2.3 2.4 2.6 2.5 
ΔGBinding (kJ/mol) -11.23 -12.18 -13.39 -14.24 
  
As compared to VLB, metabolite 10 has one extra H-bond with Asp179. The hydroxyl 
group added at C5 of VD (attached to C20) shares its electron deficient to the side chain of 
Asp179 of β-tubulin within a distance of 2.2 Å. Although the distance among the 
heteroatoms involving residues Lys336, Asn329, Val177 and Lys176 and metabolite 10 
are longer than those of VLB, an extra H-bond among the hydroxyl group at C5 of 
metabolite 10 with Asp179 strengthens the interaction of the metabolite with tubulin. Thus, 
metabolite 10 is a stronger binder than VLB (-13.39 kJ/mol vs. -11.23 kJ/mol) which 
display same binding profile as VLB. (Figure 4.2C and Table 4.3) 
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Figure 4.2: A) Structure of α- and β-tubulin coupled with docked VLB, colored in blue 
and green, respectively. Binding interactions of B) VLB, C) Metabolite 10, and D) 
Metabolite 19. Hydrogen bonds are shown in dashed lines. 
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4.4 Conclusion 
VLB binds to its target tubulin with a binding energy of -11.23 kJ/mol, and interacts with 
Lys176, Val177, Asn329 and Lys336 that belong to the vinca site [1]. Molecular docking 
simulation of metabolites of VLB into the vinca site of tubulin demonstrates that the 
majority of the metabolites have a better binding energy than their parent drug. (Table 4.2)  
Metabolite 19 has the lowest binding energy among the metabolites of VLB 
calculated to be -21.90 kJ/mol. Despite the fact that metabolite 19 interacts with Asn329 
(α-tubulin) similar to VLB, it adapts nearly similar conformation to VLB in the vinca site 
of tubulin. It interacts to more residues of β-tubulin than of α-tubulin, whereas the opposite 
is observed for VLB [5]. Hence it is possible that tubulin adapts other induced-fit 
conformation upon binding of metabolite 19. Thus, more research is required to evaluate 
whether metabolite 19 induces the same anti-mitotic effects of VLB.  
Metabolite 8, metabolite 10 and metabolite 11 have stronger binding energies than 
of VLB (-12.18 kJ/mol, -13.39 kJ/mol and -14.24 kJ/mol vs. -11.23 kJ/mol, respectively). 
They adapt similar conformation to VLB in the vinca site of tubulin and interact with the 
same residues as their parent drug (Lys176, Val177, Asn329 and Lys336) with similar or 
shorter distances in H-bonds than of VLB. This indicates their probability in causing the 
same “induced-fit” to tubulin and resulting in destabilization of the microtubules similar to 
binding of VLB. (Table 4.2 and Table 4.3) 
Metabolite 8 and metabolite 11 have similar ADMET profiles with VLB hence are 
potential analogs candidates to be taken into account for structural modifications of VLB. 
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Metabolite 10 has better PK parameters and possibly more tolerable than those of VLB, 
and thus it could provide a less unpleasant cancer therapy. 
Metabolite 10 is a unique compound due to the fact that it has the same mechanism 
of action as of VLB in the tubulin as well as a more acceptable PK profile than the 
anticancer drug. This is mainly due to the fact that metabolite has a better gastric and 
intestinal solubility, and is less bound to plasma proteins than VLB. Metabolite 10 has a 
gastric solubility (FaSSGF) (4.65 mg/mL vs. 4.61 mg/mL), intestinal solubility (FeSSIF) 
(2.95 x 10-2 mg/mL vs. 3.12 x 10-2 mg/mL) and log P (2.99 vs. 3.95) similar to VLB, which 
are all essential drug features for desired drug bioavailability. Moreover, metabolite 10 is 
less bound to plasma proteins than VLB (81.2% vs. 89.2%), thus more available throughout 
the body than VLB. (Tables 2.7 and 2.8) 
Furthermore, metabolite 10, also known as 20-Hydroxy-VLB, is not an inhibitor of 
CYP2D6 and CYP3A4 as VLB is, and thus tends to cause less drug-drug interactions and 
adverse drug reactions than its parent drug. The in silico results show that metabolite 10 
does not undergo glucoronidation, hence it has a similar phase II metabolism similar to 
VLB. (Tables 2.9 and 2.10) 
The hydroxyl group added upon metabolism of VLB producing metabolite 10 
suggests that this compound can also be a candidate for modifications of VLB to overcome 
P-gp-mediated multidrug resistance that is often observed with vinca alkaloids [10]. This 
is due to the fact that the addition of hydrophobic groups on drug molecules can potentially 
decrease their binding affinity for P-gp and likelihood of being removed out of the cell 
[11], thus enhancing drug efficacy. 
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Studies have been investigated possible analogues of VLB that display stronger 
target selectivity hence higher cytotoxicity. Chemical modifications on the catharantine 
portion of VLB (CT) at the C20ʹ ethyl substituent, such as the addition of hydrophobic 
groups, have shown significant increased potency towards destabilization of tubulin [9]. In 
a lesser extent, the vindoline portion of VLB (VD) at the C5 ethyl substituent, an important 
chemical group for biological activity of VLB, has also been chemically modified [12]. Va 
et al. have analyzed different compounds and their cytotoxic potency against cancer cell 
lines (i.e. colon cancer HCT116) by mainly modifying the C5 ethyl moiety. However, the 
chemical bond among C6 and C7 of VD was also modified to either a double or single 
bond. (Figure 1.1) 
In a C6-C7 single bond version, the addition of CH2OH group at C5 position 
(referring C19 of VD) has reduced the biological activity by 10-fold (compound 56) [12]. 
In the present work, the C6-C7 bond of VLB is double, however, Va et al. have not 
synthesized any hydrophobic moiety added on C5 ethyl in a C6-C7 double bond version 
that could mimic the same effects of the hydroxyl group of metabolite 10 into tubulin [12]. 
In addition, the hydroxyl moiety of metabolite 10 is bound to C20 of VD, and not to C19 
as the authors have investigated. This is, the chemical group (CH2)2OH of metabolite 10 is 
located at a different position from CH2OH added on C5 ethyl of compound 59 [12].  
Despite the fact that Va et al. have investigated possible chemical moieties added 
on C5 ethyl of VD that are not aligned with the hydroxyl group of metabolite 10, it can still 
display cytotoxic properties as its stereochemistry differs from compound 56. This indeed 
can facilitate the extra H-bond of metabolite 10 among its hydroxyl group at C20 and 
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Asp179, which strengthens its binding affinity for tubulin (-13.39 kJ/mol vs. -11.23 kJ/mol 
of VLB). This indicates the possibility of metabolite 10 to be a potential VLB analog that 
upon binding destabilizes microtubules. Therefore, this study provides insights into 
modifications of the chemical structure of VLB in order to make it more target-specific 
and less toxic to cancer patients suggesting that metabolite 10 can be a potential analog of 
VLB.  
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CHAPTER 5 Summary 
VLB is extensively metabolized into thirty-five known metabolites which up to date, their 
off-targets events and effects on nausea and alopecia associated receptors have not yet been 
fully determined. This in silico research project provides in-depth and novel findings on 
binding mechanisms and main interactions of VLB and its metabolites into the binding 
sites of dopaminergic D2, histaminic H1 and H3, and muscarinic M1, M4 and M5 receptors 
involved in nausea, as well as with receptors MDM2, VDR, AR and SMO involved in 
induced-alopecia. In addition, it demonstrates a detailed understanding of the in silico 
predicted pharmacokinetics properties of VLB and its metabolites along with their possible 
involvement with adverse drug reactions. Finally, the cytotoxic activity of metabolites of 
VLB is also elucidated by means of molecular docking, giving insights into potential 
analogs to be studied for VLB modifications to obtain drugs with a desired target selectivity 
for the vinca site of tubulin.   
In the inducing nausea receptors, VLB only has a better binding energy than the 
natural substrate ACh docked into M5R (-9.28 kJ/mol vs. -4.51 kJ/mol). The in silico results 
indicate that VLB does not trigger hair loss due to its low or no affinity for alopecia 
associated receptors used in this study. Thus, VLB is not expected to be involved in the 
onset of alopecia through MDM2, AR, VDR and SMO signaling pathways. However, it 
may have an effect on other alopecia associated receptors not included in this study, and 
raising the attention for further investigation of induced-alopecia by VLB. Although VLB 
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does not affect any of the alopecia receptors studied in this project, it has a significant role 
on nausea symptoms due to its binding affinity particularly for the muscarinic M5 receptor. 
Interestingly, I found that the majority of metabolites of VLB interact with nausea 
and alopecia associated receptors included in this study with significant binding affinities, 
thus capable of inducing such ADRs. They often bind to the same residues involved in the 
binding of substrates activators (ACh, dopamine, histamine, testosterone, calcitriol) or 
exogenous inhibitors (nutlin-2, TEI-4696, anta XV) of these receptors.  
In particular, the metabolites of VLB display a significant role in the activation of 
the muscarinic receptors M1, M4 and M5 involved in nausea. Although D2, H1 and H3 
receptors of nausea pathway are also affected by a few metabolites of VLB, these are not 
the major off-targets proteins of VLB metabolites in causing nausea.  
In addition, the majority of VLB metabolites have binding affinities for MDM2 
receptor, which its inhibition by the metabolites can lead to the activation of p53 and 
consequently to hair follicle apoptosis. A few metabolites also have binding affinities for 
VDR and SMO, thus may induce alopecia through different signaling pathways. Therefore, 
metabolites of VLB contribute to nausea and alopecia symptoms during treatment with 
VLB.  
Moreover, the in silico molecular docking along with the in silico predicted 
pharmacokinetics properties of VLB and its metabolites have revealed that metabolite 10 
is a potential candidate for redesign of VLB. This is because it adapts similar conformation 
to VLB in the vinca site of tubulin and has a stronger binding energy than its parent drug 
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(-13.39 kJ/mol vs. -11.23 kJ/mol). Moreover, the ADMET parameters calculated for 
metabolite 10 resemble those of VLB (i.e. gastric/intestinal solubility, log P, Vd, % 
unbound to plasma proteins, likelihood of being a substrate of CYP2D6/CYP3A4, phase 
II metabolism). Metabolite 10 also has a more tolerable pharmacokinetics profile than VLB 
which can be better accepted by patients undergoing chemotherapy. 
Therefore, through the use of molecular docking techniques and in silico ADMET 
predicted data, the novel findings of this study provide a better understanding of the 
metabolites of VLB and their binding profiles with respect to nausea (H1, H3, D2, M1, M4 
and M5) and alopecia (MDM2, VDR, AR, SMO) associated receptors. My study has 
explored how nausea and alopecia are often experienced during chemotherapy with VLB 
due to the off-target binding of VLB metabolites. In addition, this research have predicted 
the interactions of metabolites of VLB in the vinca site of tubulin, suggesting new possible 
modifications on the chemical structure of VLB for more target selectivity. This calls for 
designing simpler and target specific drugs that meet the desired drug effectiveness. 
 
